AD_____

Grant Number DAMD17-94-J-4440

TITLE: Mechanism of Retinoid Response in Human Breast Cancer

PRINCIPAL INVESTIGATOR: Xiao-kun Zhang, Ph.D.

CONTRACTING ORGANIZATION: The Burnham Institute
La Jolla, California 92037

REPORT DATE: October 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

19990811 114

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE October 1998	3. REPORT TYPE AND DATES COVERED Annual (26 Sep 97 – 25 Sep 98)

4. TITLE AND SUBTITLE
Mechanism of Retinoid Response in Human Breast Cancer

5. FUNDING NUMBERS
DAMD17-94-J-4440

6. AUTHOR(S)
Xiao-Kun Zhang, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
The Burnham Institute
La Jolla, California 92037

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT *(Maximum 200 words)*

Natural retinoids (vitamin A derivatives) and their synthetic analogs can prevent the development of breast cancer in animal. Several retinoids are now being evaluated for their ability to prevent breast cancer recurrence in patients at risk. Unfortunately, most retinoids evaluated so far do not prevent the appearance of more malignant breast cancers that have lost their dependence on estrogens for growth, consistent with in vitro observation that the anti-cancer effects of retinoic acid (RA) are mainly seen in estrogen-dependent breast cancer cell lines. Previously, we have shown that the anti-cancer effects of RA in breast cancer cells are mainly mediated by RARβ, and that RARβ is not expressed in estrogen-independent breast cancer cell lines. In the past funding year, we convincingly demonstrated that RXR-selective retinoids, through a new mechanism of action, can induce RARβ expression and growth inhibition in estrogen-independent breast cancer cells, revealing a novel growth inhibition pathway. In addition, we observed that retinoid activities in breast cancer cells is regulated by BAG-1, a recently identified cell survival gene that can interact with BCL-2, providing a possible molecular basis for interaction between retinoid and apoptosis signalings.

14. SUBJECT TERMS
Breast Cancer
Retinoids, Retinoid Receptors, Orphan Receptors

15. NUMBER OF PAGES
30

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18 298-102

USAPPC V1.00

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

__✓__ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

_____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

__✓__ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

__✓__ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

__✓__ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature   10/23/98
                                  Date

3

TABLE OF CONTENTS

	Page

INTRODUCTION

Retinoids, vitamin A and its analogs, are promising chemopreventive agents against breast cancer. Their efficacy against mammary carcinogenesis in animal models has been demonstrated by their ability to increase the latency period for tumor appearance and decrease the number of animals with cancer (1). Despite their cancer preventive effects, retinoids tested in clinical trials have not yet caused major clinical responses (2, 3), implying that their anti-cancer effectiveness diminishes in more malignant cells and leads to one of the major drawbacks in retinoid therapy, the retinoid resistance. The ineffectiveness of the tested retinoids in the treatment of patients with advanced breast cancer is consistent with in vitro observations that the anti-cancer effects of retinoic acid (RA) are mainly seen in estrogen-dependent breast cancer cells and that, upon progression of the disease to estrogen independence, breast cancer cells become refractory to RA.

The effects of retinoids are mainly mediated through the three types (α, β, and γ) of the RA receptors (RARs) and retinoid X receptors (RXRs), which function in vivo mainly as RXR/RAR heterodimers (4-6). The RXR/RAR heterodimers are activated by RAR ligands. Binding of RXR ligands can induce RXR homodimer formation and function (6) and may be required for activation of certain RXR-containing heterodimers, such as RXR/LXR (7) and RXR/nur77 (8, 9). The dimeric complexes of retinoid receptors function as transcriptional factors that bind to specific sequences on target genes and regulate the transcriptional expression of the genes. One of the most potent target genes identified so far is RARβ gene. RARβ is activated by RA through a RA response element (βRARE) in its promoter (10). The auto-induction of RARβ expression may play a critical role in amplifying retinoid responses.

Regulation of gene expression either positively or negatively by nuclear hormone receptors is modulated by additional cofactors that appear to provide a direct link to the core transcriptional machinery and to modulate chromatin structure (11). Some of these cofactors (coactivators) enhance transactivation by several nuclear receptors in the presence of their cognate ligands, whereas others (corepressors) are necessary for unliganded receptors to silence the activity of target promoters, and are dissociated upon binding of ligand to the receptors.

Despite intensive research, the molecular mechanisms by which retinoids exert their anti-cancer effects and how their activities are lost in certain breast cancer cells remain unclear. The major goal of the proposed experiments is to understand the molecular mechanism by which retinoids exert their anti-cancer effects in breast cancer cells. The specific aims of this project are: 1) to analyze the anti-estrogen effect of retinoid receptors; 2) to characterize proteins that interact with RXR; 3) to analyze transactivation and anti-AP-1 activities of retinoid receptors; 4) to analyze the mechanism by which retinoid receptor activities are impaired, and 5) to analyze the function of RXR homodimers.

Despite a sudden leave of a postdoctoral working on this project, we have made substantial progress toward these specific aims in the past funding year.

Our results convincingly demonstrate that RXR ligands are functional in estrogen-independent breast cancer cells, through activation of RXR/nur77 heterodimers that induce RARβ expression and subsequently growth inhibition and apoptosis. We have developed a class of RARβ-selective antagonists to study RARβ function. We have also observed that BAG-1 plays a critical role in the regulation of RAR and RXR activity in breast cancer cells through their direct protein-protein interaction.

BODY

Growth inhibitory effect of receptor-selective retinoids in breast cancer cell lines. We have shown that RAR-selective ligand, *trans*-RA, can effectively inhibit the growth and induce apoptosis in estrogen-dependent breast cancer cell lines through its ability to induce RARβ expression (12). We further investigated the role of RARs and RXRs in estrogen-dependent and –independent breast cancer cell lines by using a number of RAR-selective and RXR-selective retinoids. Our data showed that RAR-selective retinoids strongly inhibited the growth of estrogen-dependent ZR-75-1 cells, but not estrogen-independent cells, whereas RXR-selective retinoids did not affect estrogen-dependent cell growth, but significantly inhibited the growth of estrogen-independent MDA-MB-231 cells. RXR-selective retinoid also induced apoptosis in estrogen-independent cells but not in estrogen-dependent cells, whereas RAR-selective but not RXR-selective retinoid induced apoptosis in ZR-75-1 cells. These data demonstrate that different retinoid signaling pathways can mediate retinoid-induced growth inhibition in estrogen-dependent and -independent breast cancer cells.

Induction of RARβ expression RXR-selective retinoids in estrogen-independent breast cancer cells. Since the growth inhibitory effect of retinoids is mainly mediated by RARβ, we analyzed whether the growth inhibitory effect of RXR-selective retinoids in estrogen-independent breast cancer cells is due to their induction of RARβ. Our results showed that RXR-selective retinoids could induce RARβ in *trans*-RA-resistant MDA-MB-231 cells but not in estrogen-dependent ZR-75-1 and T-47D cells. Thus, our data demonstrate that RARβ induction and activation correlates with growth inhibition and suggest that RARβ induction may contribute to growth inhibition by RXR-selective retinoids in estrogen-independent breast cancer cells.

Inhibition of RARβ activity by RARβ-selective antagonists reduces growth inhibitory effect of RA in breast cancer cells. To provide a more direct evidence that RARβ induction is responsible for the growth inhibitory effect of RA in breast cancer cells, we have developed a class of RARβ-selective antagonists, in collaboration with Dr. Yuichi Hashimoto at the University of Tokyo. These antagonists, when used together with RA, strongly reduced the growth inhibitory effect of RA in breast cancer cells (Figure 1a). In addition, apoptosis-inducing effect of RA was largely abolished by these antagonists (Figure 1b). Thus, activation of RARβ can lead to growth inhibition and apoptosis of breast cancer cells.

a.

b.

Figure 1. RARβ-selective antagonists inhibit growth inhibition and apoptosis induction by RA in breast cancer cells. **a)** effect of RARβ-selective antagonists on RA-induced growth inhibition in ZR-75-1 breast cancer cells. ZR-75-1 cells were seeded at a cell density of 1,000 cells/well in 96-well plates and treated with our without 10^{-7}M *trans*/RA in the absence of presence of the indicated concentration of RARβ-selective antagonists LE135, LE540 or LE550 for 10 days and the cell viability was determined by the MTT assay. **b) effect of RARβ-selective antagonists on RA-induced apoptosis in ZR-75-1 breast cancer cells.** ZR-75-1 cells were treated with or without 10^{-7}M *trans*-RA in the absence of presence of 10^{-6}M LE135, LE540 or lE550 for 3 days and DNA fragmentation was determined by the TdT assay. Representative histograms show relative apoptotic cell numbers.

Effect of RXR-selective retinoids on RARβ induction is mediated by RXR/nur77 heterodimers. We investigated how induction of RARβ by RXR-selective retinoids is mediated. Our results demonstrate that the βRARE in the RARβ gene promoter mediates RARβ expression. The βRARE is activated by the RXR/RAR heterodimer in response to RAR-selective retinoids, but not RXR-selective retinoids. However, our gel retardation assay showed that the βRARE could also bind to RXR/nur77 heterodimer with high affinity. To determine whether binding of the RXR/nur77 heterodimers to the βRARE could activate the response element in response to RXR-selective retinoids, we performed a transient transfection assay. Cotransfection of nur77 and RXR expression vectors significantly enhance the βRARE activity in response to RXR-selective retinoids. This data suggests that induction of RARβ by RXR-selective retinoids through RXR/nur77 heterodimers may be the mechanism by which RXR-selective retinoids inhibit the growth of MDA-MB-231 cells. Many estrogen-dependent and -independent breast cancer cell lines have similar expression levels of RARγ and RXRα. Nur77 expression levels are similar in ZR-75-1 and MDA-MB-231 cells. However, RARα is only highly expressed in the estrogen-dependent breast cancer cell lines. This suggests the possibility that expression of RARα may allow preferential formation of RARα/RXR heterodimers in estrogen-dependent breast cancer cell lines, that function to mediate the growth inhibitory effect of RAR-selective retinoids but not RXR-selective retinoids. In contrast, low expression level of RARα in estrogen-independent breast cancer cell lines may permit formation RXR/nur77 heterodimers that can be activated by RXR-selective retinoids to induce RARβ. Therefore, depending on the RAR, RXR, and nur77 levels of present in the cancer cells, either the RAR or RXR-signaling pathway can activate the

βRARE. This retinoid signaling switch may play an important role in regulating cell growth in response to different types of retinoids.

Modulation of retinoid activity by BAG-1 in breast cancer cells. BAG-1 (also known as RAP46) is an anti-apoptotic protein that was cloned from a murine embryo cDNA library based on its ability to interact with Bcl-2 (13). Co-expression of BAG-1 and Bcl-2 in Jurkat lymphoid cells, NIH 3T3 fibroblasts, and melanoma cells promoted the survival of these cells in response to a variety of apoptotic stimuli (14). In addition to Bcl-2, BAG-1 also interacts with Raf-1 (15), and can activate this kinase through a Ras-independent mechanism. Furthermore, BAG-1 can interact with hepatocyte growth factor (HGF) receptor and with platelet-derived growth factor (PDGF) receptor, and enhance the ability of these receptors to transduce signals for cell survival (16). These observations suggest that BAG-1 may function as an adaptor to mediate the interaction between survival factors and apoptotic machinery, and may also play a role in regulating cellular proliferation. Interestingly, BAG-1 was also cloned from human liver cDNA library by virtue of its interaction with the glucocorticoid receptor (17). We studied whether BAG-1 interacts with RAR. Gel retardation assays demonstrated that in vitro translated BAG-1 protein could effectively inhibit the binding of RAR/RXR to the βRARE. A glutathione S-transferase (GST)-BAG-1 fusion protein also specifically bound RAR. Interaction of BAG-1 and RAR could also be demonstrated by yeast two-hybrid assays. In transient transfection assays, co-transfection of BAG-1 inhibited the transactivation activity of RAR/RXR heterodimers. When stably expressed in both MCF-7 and ZR-75-1 breast cancer cell lines, BAG-1 suppressed RA-induced growth inhibition and apoptosis. In addition, RA-induced suppression of Bcl-2 expression was abrogated by over-expression of BAG-1. These results demonstrate that BAG-1 can physically interact with RARs and is an important component of the retinoid response pathway. The findings suggest that this protein-protein interaction may play an important role in the regulation of retinoid-induced growth inhibition and apoptotic processes, potentially contributing to retinoid resistance in breast cancer.

Differential regulation of RAR and RXR activity by GAB-1 is mediated by Hsp70. We also analyzed the effect of BAG-1 on RXR homodimer activity and found the BAG-1 could strongly enhance transactivation activity of RXR homodimer (Figure 2). Since BAG-1 is known to interact with Hsp70, we studied whether the effect of BAG-1 is mediated by Hsp70 that can interact with either RAR or RXR (Figure 3). In GST- pull-down assay, we observed that Hsp70 could inhibit interaction between RAR and BAG-1 whereas interaction between RXR and BAG-1 was enhanced by Hsp70. These data suggest that the inhibitory effect of BAG-1 on RAR may be due to its reduction of RAR/Hsp70 interaction while the stimulatory effect of BAG-1 on RXR is likely attributed to the stabilization of RXR/Hsp70 complex by BAG-1.

RXRα (25 ng)	+	+	+	+	+
9-cis RA	−	+	+	+	+
BAG-1 (ng)	−	−	10	20	50

RARα (50 ng)	+	+	+	+	+
trans-RA	−	+	+	+	+
BAG-1 (ng)	−	−	10	20	50

Figure 2. Enhancement of RXR homodimer activity by BAG-1. The TREpal-tk-CAT reporter plasmid was co-transfected into CV-1 cells with 20 ng of RXRα expression vector together with the indicated amount of GAB-1 expression vector. Transfected cells were treated with or without $10^{-7}M$ 9-cis-RA and assayed 24 hours later for CAT activity. For comparison, the inhibitory effect of BAG-1 on RAR activity is shown.

GST-RAR GST-RXR

Hsp-70 →

Figure 3. Interaction of Hsp-70 with RAR and RXR. GST-RAR or GST-RXR fusion protein immobilized on glutathione-Sepharose beads was mixed with Hsp-70 protein. After extensive washing, the bound Hsp-70 was analyzed by SDS-polyacrylamide gel electrophoresis and western blotting using anti-Hsp-70 antibody.

GST-RAR	−	+	+	−	−	−	−	−
GST-RXR	−	−	−	−	−	+	+	−
Hsp-70	−	−	+	+	−	−	+	+
BAG-1	+	+	+	+	+	+	+	+
GST	+	−	−	+	+	−	−	+

BAG-1 →

Figure 4. Hsp-70 differentially effects interaction between BAG-1 and RAR or RXR. GST-RAR or GST-RXR immobilized on glutathione-Sepharose beads was mixed with BAG-1 in the absence of presence of Hsp-70. The interaction between BAG-1 and RAR or BAG-1 and RXR was analyzed by Western blotting using anti-BAG-1 antibody.

9

CONCLUSION

Research conducted in the past funding year shows several pieces of exciting findings. We have now convincingly demonstrated that activation of RXR by RXR-selective retinoids can induce growth inhibition in estrogen-independent, *trans*-RA-resistant breast cancer cells. The effect of RXR-selective retinoids is mediated through RXR/nur77 heterodimers that bind to the βRARE and induce RARβ gene expression in response to RXR ligands. This finding is important in that we demonstrate a novel growth inhibition pathway that is mediated by activation of RXR. Importantly, the pathway is functional in estrogen-independent and *trans*-RA-resistant breast cancer cells. Thus, different retinoid growth inhibition pathways exist and different classes of retinoids can be used for different types of breast cancer. We have also developed a class of RARβ-selective antagonists that will be useful for studying RARβ function in breast cancer cells. Furthermore, we observed that retinoid receptors could interact with a cell survival gene, BAG-1, suggesting that BAG-1 can regulate retinoid activity through its interaction with RARs or RXRs and may mediate the interaction among retinoid, growth and apoptosis signalings. Our data demonstrates that the effect of BAG-1 on retinoid receptor is mediated by Hsp-70. As proposed, in the coming year we will further investigate the molecular mechanism by which retinoid receptors function in breast cancer cells. Due to our finding of the involvement of orphan receptors nur77 in regulating retinoid activity, our research will focus on the mechanism by which RXR/nur77 heterodimers mediate the effect of RXR-selective retinoids. In addition, we will further investigate the mechanism by which BAG-1 interacts with retinoid receptors and regulates retinoid activities in breast cancer cells.

REFERENCES

1. Moon, R. C. , Mehta, R. G., and Rao, K.V.N. Retinoids and cancer in experimental animals. In *The Retinoids: Biology, Chemistry, and Medicine*, 2nd ed. M. B. Sporn, A. B. Roberts, and D. S. Goodman (Eds.), Raven Press, New York, 1994, pp. 573-595.

2. Cassidy, J., Lippman, M., LaCroix, A., *et al.* Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. *Eur. J. Cancer Clin. Oncol.* **18**: 925-928, 1982.

3. Modiano, M., Dalton, W., Lippman, S., *et al.* Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. *Invest. New Drugs* **8**: 317-319, 1990.

4. Mangelsdorf, D. J., and Evans, R. M. The RXR heterodimers and orphan receptors. *Cell* **83**: 841-850, 1995.

5. Kastner, P., Mark, M., and Chambon, P. Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life? *Cell* **83**:859-869, 1995.

6. Zhang, X-k., and Pfahl, M. Regulation of retinoid and thyroid hormone action through homodimeric and heterodimeric receptors. *Trends Endocrinol. Metab.* **4**: 156-162, 1993.

7. Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A. and Mangelsdorf, D. J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. *Genes Dev.* **9**:1033-45, 1995.

8. Forman, B. M., Umesono, K., Chen, J., and Evans, R. M. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. *Cell* **81**: 541-550, 1995.

9. Perlmann, T., and Jansson, L. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and Nurr1. *Genes Dev.* **9**: 769-782, 1995.

10. Hoffmann, B., Lehmann, J. M., Zhang, X-k., Hermann, T., Graupner, G., and Pfahl, M. A retinoic acid receptor-specific element controls the retinoic acid receptor-β promoter. *Mol. Endocrinol.* **4**: 734-1743, 1990.

11. Horwitz,K.B., Jackson,T.A., Bain,D.L., Richer,J.K., Takimoto,G.S. and Tung,L. Nuclear receptor coactivators and corepressors. *Mol. Endocrinol.*, **10**, 1167-1177, 1996.

12. Liu, Y., Lee, M.-O., Wang, H.-G., Li, Y., Hashimoto, Y., Klaus, M., Reed, J. C., and Zhang, X.-k. RARβ mediates the growth inhiitory effect of retinoic acid by inducing cell apoptosis in human breast cancer cells. *Mol. Cell. Biol.* **16**: 1138-1149, 1996.

13. Takayama,S., Sato,T., Krajewski,S., Kochel,K., Irie,S., Millan,J.A. and Reed,J.C. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. *Cell* **80**: 279-284, 1995.

14. Wang,H.-G., Takayama,S., Rapp,U.R. and Reed,J.C. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. *Proc. Natl. Acad. Sci. USA* **93**: 7063-7068, 1996.

15. Bardelli,A., Longati,P., Albero,D., Goruppi,S., Schneider,C., Ponzetto,C. and Comoglio,P.M. HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. *EMBO J* **15**: 6205-6212, 1996.

16. Zeiner,M. and Gehring,U. A protein that interacts with members of the nuclear hormone receptor family: identification and cDNA cloning. *Proc. Natl. Acad. Sci. USA* **92**: 11456-11469, 1995.

17. Takayama,S., Bimston,D.N., Matsuzawa,S., Freeman,B.C., Aime-Sempe,C., Xie,Z., Morimoto,R.I. and Reed,J.C. BAG-1 modulates the chaperone activity of Hsp70/Hsc70. *EMBO J.* **16**: 4887-4896, 1997.

18. Pratt,W.B. and Toft,D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr. Rev.* **18**: 306-360, 1997.

APPENDIX

1. Wu, Q., Cheng, Y., Dawson, M.I., Hobbs, P.D., Li, Y., and Zhang, X.-k. Inhibition of trans-RA-resistant human breast cancer cell growth by retinoid X-receptor-selective retinoids. **Mol. Cell. Biol.** 17: 6598-6608, 1997.

2. Liu,R., Takayama, S., Zheng, Y., Froesch, B., Chen, G-q., Zhang, X., Reed, J.C. and Zhang, X.-k. Interaction of BAG-1 with retinoic acid receptor and its inhibition of retinoic acid-induced apoptosis in breast cancer cells. **J. Biol. Chem.** 273: 16985-16992, 1998.

Inhibition of *trans*-Retinoic Acid-Resistant Human Breast Cancer Cell Growth by Retinoid X Receptor-Selective Retinoids

QIAO WU,[1] MARCIA I. DAWSON,[2] YUN ZHENG,[1] PETER D. HOBBS,[2] ANISSA AGADIR,[1]
LING JONG,[2] YIN LI,[1] RU LIU,[1] BINGZHEN LIN,[1] AND XIAO-KUN ZHANG[1]*

*The Burnham Institute, La Jolla Cancer Research Center, La Jolla, California 92037,[1] and
Retinoid Program, SRI International, Menlo Park, California 94025[2]*

All-*trans*-retinoic acid (*trans*-RA) and other retinoids exert anticancer effects through two types of retinoid receptors, the RA receptors (RARs) and retinoid X receptors (RXRs). Previous studies demonstrated that the growth-inhibitory effects of *trans*-RA and related retinoids are impaired in certain estrogen-independent breast cancer cell lines due to their lower levels of RARα and RARβ. In this study, we evaluated several synthetic retinoids for their ability to induce growth inhibition and apoptosis in both *trans*-RA-sensitive and *trans*-RA-resistant breast cancer cell lines. Our results demonstrate that RXR-selective retinoids, particularly in combination with RAR-selective retinoids, could significantly induce RARβ and inhibit the growth and induce the apoptosis of *trans*-RA-resistant, RARα-deficient MDA-MB-231 cells but had low activity against *trans*-RA-sensitive ZR-75-1 cells that express high levels of RARα. Using gel retardation and transient transfection assays, we found that the effects of RXR-selective retinoids on MDA-MB-231 cells were most likely mediated by RXR-nur77 heterodimers that bound to the RA response element in the RARβ promoter and activated the RARβ promoter in response to RXR-selective retinoids. In contrast, growth inhibition by RAR-selective retinoids in *trans*-RA-sensitive, RARα-expressing cells most probably occurred through RXR-RARα heterodimers that also bound to and activated the RARβ promoter. In MDA-MB-231 clones stably expressing RARα, both RARβ induction and growth inhibition by RXR-selective retinoids were suppressed, while the effects of RAR-selective retinoids were enhanced. Together, our results demonstrate that activation of RXR can inhibit the growth of *trans*-RA-resistant MDA-MB-231 breast cancer cells and suggest that low cellular RARα may regulate the signaling switch from RAR-mediated to RXR-mediated growth inhibition in breast cancer cells.

Retinoids, the natural and synthetic vitamin A analogs, exert profound effects on cell proliferation, differentiation, and apoptosis (19, 36, 50) and are considered promising agents for the prevention and treatment of human cancers, including breast cancer (36, 43, 50). Retinoids, alone or in combination with an antiestrogen or interferons, inhibit the in vitro growth of human breast cancer cells (12–14, 29, 34, 51, 60–62). The natural retinoid derivative retinyl methyl ether (18) and the synthetic retinoids *N*-(4-hydroxyphenyl) retinamide (4-HPR) (44, 45) and LGD1069 (17) effectively inhibited the development of carcinogen-induced mammary cancers in animals. Unfortunately, clinical trials on patients with advanced breast cancer showed no significant activity for retinoids (2, 3, 42). These studies indicate that retinoids are effective inhibitors of the cancer cells at the early stages of tumor progression and that their effectiveness diminishes as cells become more malignant and invasive. They are also consistent with well-documented in vitro observations that growth inhibition by all-*trans*-retinoic acid (*trans*-RA) and related retinoids occurs mainly in estrogen-dependent, estrogen receptor-positive breast cancer cells and that upon progression to estrogen independence and loss of the estrogen receptor, most breast cancer cells become refractory to growth inhibition by *trans*-RA (14, 34, 54, 55, 60).

The effects of retinoids are mainly mediated by two classes of nuclear receptors, the RA receptors (RARs) and retinoid X receptors (RXRs) (28, 38, 70). 9-*cis*-RA is a high-affinity natural ligand for both RARs and RXRs, whereas *trans*-RA is a high-affinity natural ligand only for the RARs. RARs and RXRs are each encoded by three distinct genes (α, β, and γ) and are members of the steroid/thyroid hormone/retinoid receptor superfamily, which function as ligand-activated transcription factors (28, 38, 70). RARs interact with RXRs, forming RXR-RAR heterodimers that bind to RA response elements (RAREs) to control the expression of RA-responsive genes in the presence of retinoids. Transcriptional regulation of RA-responsive genes is also modulated by a number of cofactors that appear to provide a direct link to the core transcriptional machinery and/or to modulate chromatin structure (reference 27 and references therein). Although RXR acts as a silent heterodimerization partner of RAR in CV-1 cells (15, 30, 38), recent studies demonstrate that binding of certain RXR ligands contributes to activation of RXR-RAR heterodimers in some cell types (4, 31, 40, 52, 59, 71). In the presence of 9-*cis*-RA, RXRs can also function as homodimers that bind a set of specific DNA sequences (68, 70, 71). Furthermore, activation of RXR is required for the function of other RXR-containing heterodimers, such as RXR-nur77 (15, 49) and RXR-LXR (63). Thus, distinct retinoid signaling pathways through activation of either RAR or RXR exist; however, the role of RXR activation in these pathways requires clarification.

RA target genes, including those for the RARs, have been identified. The RARE (βRARE) in the RARβ gene promoter mediates *trans*-RA-induced RARβ gene expression in many different cell types (10, 21, 57) and binds both RXR-RAR (28, 38, 70) and RXR-nur77 (15, 49) heterodimers. Gene transcriptional activation by RXR-RAR binding is mainly activated by RAR-specific ligands, while transactivation by RXR-nur77 is induced by RXR-specific ligands (15, 49). These observations

---

* Corresponding author. Mailing address: The Burnham Institute, La Jolla Cancer Research Center, 10901 N. Torrey Pines Road, La Jolla, CA 92037. Phone: (619) 646-3141. Fax: (619) 646-3195. E-mail: xzhang@ljcrf.edu.

suggest that RARβ can be induced by both RAR- and RXR-specific ligands. nur77 is an orphan member of nuclear receptor superfamily that regulates gene expression by binding to the nur77-binding response element (NBRE) as a monomer (64). It is rapidly induced by various stimuli, including growth factors and phorbol ester- and cyclic AMP-dependent synthesis pathways (20, 39). Recent studies suggest that nur77 is involved in activation-induced apoptosis of T cells (35, 65) and is associated with *trans*-RA resistance in human lung cancer cells (66). Thus, RARβ expression is regulated by growth signals and may be associated with the apoptotic process.

Recently, evidence has emerged that the absence or aberrant expression of RARβ correlates with malignancy and may contribute to the development of cancers. The involvement of RARβ in cancer development was originally implicated in the finding that the RARβ gene is integrated by hepatitis B virus in human liver cancer (9). Subsequent reports indicate that abnormal expression of the RARβ gene appears to be involved in the tumorigenicity of human papillomavirus type 18-transformed ovarian cancer cells (1) and the neoplastic progression of human oral squamous cell carcinoma cell lines (24), and it is observed in many other human cancer cell lines (16, 22, 24, 34, 48, 58, 69). RARβ also suppresses the growth of breast cancer cells (33, 34, 58) and lung cancer cells (23). The auto-induction of RARβ gene expression presumably plays a critical role in amplifying retinoid responses and is associated with the growth-inhibitory effects of *trans*-RA in breast cancer cells in vitro (34) and the clinical response to retinoids in patients with premalignant oral lesions (37). Retinoids that fail to induce RARβ expression cannot arrest the growth of melanoma cells (5).

The involvement of retinoid receptors in mediating retinoid-induced growth inhibition and apoptosis has been investigated. Several studies demonstrated that expression of RARα mediates the growth-inhibitory effect of *trans*-RA in estrogen-dependent breast cancer cells and that the loss of *trans*-RA sensitivity in estrogen-independent cells may be due to low levels of RARα (34, 51, 55, 60). RARα levels are higher in certain estrogen-dependent, *trans*-RA-sensitive breast cancer cell lines, such as ZR-75-1, MCF-7, and T-47D, than in certain estrogen-independent, *trans*-RA-resistant cells lines, such as MDA-MB-231 and MDA-MB-468 (34, 51, 55, 60). Expression of RARα in estrogen-independent, *trans*-RA-resistant MDA-MB-231 breast cancer cells restored *trans*-RA sensitivity (34, 54, 55, 61). Growth inhibition induced by retinoids in estrogen-dependent MCF-7 breast cancer cells correlated with their binding affinity to RARα (7). The involvement of RARβ was suggested by the observation that it was expressed in response to *trans*-RA in certain estrogen-dependent, *trans*-RA-sensitive breast cancer cell lines, such as ZR-75-1 and T-47D, but not in estrogen-independent, *trans*-RA-resistant cell lines MDA-MB-231, MDA-MB-468, and BT-20 (34). In addition, we (34) and others (33, 53) demonstrated that introduction of RARβ into MDA-MB-231 cells led to the recovery of *trans*-RA-induced growth inhibition. Moreover, RARβ expression was enhanced in RARα stably transfected MDA-MB-231 cells, a finding that suggests that RARβ may mediate the growth inhibitory effects of RARα (34). The role of RARβ in growth inhibition is also supported by the observation that as normal human mammary epithelial cells senesce, RARβ mRNA expression increases (58). RARγ is highly expressed in various breast cancer cell lines independently of their estrogen responsiveness (34) and is unlikely involved in regulating *trans*-RA-induced growth inhibition and apoptosis. However, recent studies (11, 12) have demonstrated that it may play a role in mediating growth inhibition and apoptosis induction by 4-HPR and certain synthetic retinoids. 4-HPR was a potent transactivator of RARγ at concentrations that inhibited the growth and induced apoptosis of breast cancer cells (11). Furthermore, growth inhibition by certain receptor-selective retinoids and interferons was associated with increased expression of RARγ (12). Thus, different retinoid receptors, which may function through different mechanisms, can mediate growth inhibition and apoptosis induction by different types of retinoids in breast cancer cells.

In this study, we evaluated the effects of RAR- and RXR-class selective retinoids on the growth of *trans*-RA-resistant, RARα-deficient MDA-MB-231 cells. Our results demonstrate that RXR-selective retinoids induced RARβ expression, growth inhibition, and apoptosis in these cells, most likely through their activation of RXR-nur77 heterodimers that bind to the RARβ promoter. When we stably expressed RARα in MDA-MB-231 cells, we observed an enhanced growth inhibition and RARβ induction by RAR-selective retinoids and decreased effects by RXR-selective retinoids, similar to those observed in *trans*-RA-sensitive, RARα-expressing breast cancer cells, such as ZR-75-1 cells. Thus, an RXR-mediated growth inhibition pathway exists in breast cancer cells and is regulated by RARα levels. These results may provide a novel method for inhibiting the growth of the more malignant *trans*-RA-resistant breast cancer cells.

MATERIALS AND METHODS

Retinoids. *trans*-RA was obtained from Sigma (St. Louis, Mo.). SR11246, SR11237, and SR11235 were prepared as described by Dawson et al. (8). Synthesis of SR11383 was described elsewhere (16a).

(*E*)-3-[4-(1-Methoxy-5,6,7,8-tetrahydro-1-5,5,8,8-tetramethyl-3-naphthalenyl) phenyl]propenoic acid (SR11278) was synthesized as follows. (i) Cyclialkylation [AlCl$_3$, (CH$_2$Cl)$_2$, 0°C] of 3-bromoanisole with 2,5-dichloro-2,5-dimethylhexane as reported by Kagechika et al. (26) yielded 3-bromo-1-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene (71%), which was coupled under Suzuki conditions {Pd[P(C$_6$H$_5$)$_3$]$_4$, NaHCO$_3$, aqueous 1,2-dimethoxyethane [MeO (CH$_2$)$_2$OMe], reflux} (41) with 4-formylphenylboronic acid to give 4-(1-methoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-3-naphthalenyl)benzaldehyde (91%). (ii) Horner-Emmons olefination of this benzaldehyde with triethyl phosphonoacetate [KN(SiMe$_3$)$_2$, tetrahydrofuran-toluene, –78 to 25°C] produced the ethyl ester of SR11278 (97%). (iii) Hydrolysis (KOH, aqueous ethanol [EtOH]; aqueous HCl) gave SR11278 (99%): melting point (mp), 179 to 182°C; ^{1}H nuclear magnetic resonance (NMR) (300 MHz, ^{2}HCCl$_3$) δ 1.34 (s, 6, CMe$_2$), 1.41 (s, 6, CMe$_2$), 1.68 (m, 4, CH$_2$CH$_2$), 3.89 (s, 3, OMe), 6.49 (d, *J* = 16.0 Hz, 1, C=CHCO$_2$), 6.90 (d, *J* = 1.8 Hz, 1, ArH), 7.20 (d, *J* = 1.8 Hz, 1, ArH), 7.62 (s, 4, ArH), 7.83 (d, *J* = 16.0 Hz, 1, *H*C=CCO$_2$); infrared (IR) (KBr) 2,955, 1,700, 1,630, 1,430, 1,278, 1,220, 825 cm^{-1}.

4-[(3-Hydroxy-5,6,7,8-tetrahydro-3,5,5,8,8-tetramethyl-2-naphthalenyl)carboxyamido]benzoic acid (SR11281) was synthesized as follows. (i) Fries rearrangement (AlCl$_3$, 130°C [23]) of 2-acetoxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene produced 1-(3-hydroxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthalen-2-yl)ethanone (90%). (ii) Protection of the phenolic group as the benzyl ether (benzyl bromide, K$_2$CO$_3$, acetone, reflux; 92%) and oxidation of the acetyl group (NaOCl, EtOH, reflux) gave 3-benzyloxy-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxylic acid (30%). (iii) The carboxylic acid was converted (oxalyl chloride, CH$_2$Cl$_2$) to the acyl chloride and treated (pyridine-benzene) with ethyl 4-aminobenzoate to yield the benzamide (95%). (iv) Ester hydrolysis (NaOH, aqueous EtOH, 25°C; aqueous HCl; 97%) and hydrogenolysis [H$_2$, Pd(C), EtOH, 25°C; 93%] of the benzyl ether gave SR11281: mp, 275 to 278°C; ^{1}H NMR (300 MHz, ^{2}HCCl$_3$) δ 1.29 (s, 6, CMe$_2$), 1.32 (s, 6, CMe$_3$), 1.69 (s, 4, CH$_2$CH$_2$), 6.93 (s, 1, ArH), 7.69 (s, 1, ArH), 7.74 (d, 2, *J* = 8.8 Hz, ArH), 8.08 (d, 2, *J* = 8.8 Hz, ArH); IR (KBr) 3,330, 1,686, 1,530, 1,419, 1,174 cm^{-1}.

4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-methylpropenyl]benzoic acid (SR11345) was prepared by Suzuki Pd(0)-catalyzed coupling {Pd[P(C$_6$H$_5$)$_3$]$_4$, NaHCO$_3$, aqueous MeO(CH$_2$)$_2$OMe, reflux; 58%} (8) between 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalene-2-boronic acid and methyl (1-bromo-2-methylpropenyl)benzoate and hydrolysis (KOH, aqueous EtOH; aqueous HCl; 91%). The first intermediate was synthesized in two steps by bromination (Br$_2$, CHCl$_3$, 25°C; 80%) of 5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphthalene, followed by conversion to the arylboronic acid [*n*-butyllithium (*n*-BuLi), tetrahydrofuran (THF), –78°C to ambient temperature; B(OMe)$_3$, –78°C to ambient temperature; aqueous NH$_4$Cl; 86%]. The second intermediate was obtained from methyl (2-methylpropenyl)benzoate by bromination (Br$_2$, CH$_2$Cl$_2$; 100%) and dehydrobromination {1,8-diazabicyclo[5.4.0]undec-7-ene, MeO(CH$_2$)$_2$OMe, 25°C; 90%} to yield SR11345: mp, 246 to 247°C; ^{1}H NMR

(^{2}HCCl$_3$) δ 1.25 (s, 12, 4CH$_3$), 1.64 (s, 3, CH$_3$), 1.66 (s, 3, CH$_3$), 1.88 [s, 4, (CH$_2$)$_2$], 1.99 (s, 3, CH$_3$), 7.00 (s, 1, ArH), 7.03 (s, 1, ArH), 7.25 (d, J = 8.3, 2, ArH), 7.98 (d, J = 8.3, 2, ArH); IR (KBr) 3,500 to 2,300 (OH), 1,687 (C = O), 1,606 (C = C) cm^{-1}; chemical ionization high-resolution mass spectrum (CI-HRMS) (NH$_3$) calculated for C$_{26}$H$_{32}$O$_2$ + NH$_4^+$, 394.2746; found, 394.2751.

4-(1-Amino-5,6,7,8-tetrahydro-5,5,8,8-tetramethylanthracen-2-yl)benzoic acid (SR11350) was synthesized by nitration (HNO$_3$, acetic anhydride-acetic acid [Ac$_2$O-HOAc], −10°C) of 6-bromo-1,2,3,4-tetrahydro-1,1,4,4-tetramethylanthracene to give after chromatographic separation (silica, CH$_2$Cl$_2$-hexanes) of isomers 6-bromo-1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-5-nitroanthracene (26%), which was coupled {Pd[P(C$_6$H$_5$)$_3$]$_4$, NaHCO$_3$, aqueous dimethyl ether (DME), 80°C; 83%} to 4-carbethoxyphenylboronic acid to afford ethyl 4-(1-nitro-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-anthracen-2-yl)benzoate. Hydrogenation [H$_2$, Pd(C), EtOAc, 25°C; 95%) to the amine and ester hydrolysis (KOH, aqueous EtOH; 85°C; aqueous HCl; 93%) yielded SR11350 as the HCl: salt mp, 267 to 268°C; ^{1}H NMR (300 MHz, Me$_2$SO-^{2}H$_6$) δ 1.40 (s, 6, CH$_3$), 1.44 (s, 6, CH$_3$), 1.77 (s, 4, CH$_2$), 7.25 (d, J = 8.6 Hz, 1, ArH) 7.55 (d, J = 8.6 Hz, 1, ArH), 7.55 (d, J = 8.2 Hz, 2, ArH), 7.90 (s, 1, ArH), 8.11 (d, J = 8.2 Hz, 2, ArH), 8.21 (s, 1, ArH); electron impact high-resolution mass spectrum (EI-HRMS) calculated for C$_{25}$H$_{27}$NO$_2$, 373.2042; found, 373.2040.

6-[3-(1-Adamantyl)-5-methoxyphenyl]naphthalene-2-carboxylic acid (SR11362) was obtained by hydrolysis (KOH, aqueous EtOH, 85°C; aqueous HCl; 90%) of its ethyl ester: mp, 236 to 238°C; ^{1}H NMR (300 MHz, ^{2}HCCl3) δ 1.79 (m, 6, CH$_2$), 1.98 (m, 6, CH$_2$), 2.12 (m, 3, CH), 3.87 (s, 3, OCH$_3$), 6.96 (s, 1, ArH), 7.02 (s, 1, ArH), 7.28 (s, 1, ArH), 7.75 (m, 1, ArH), 7.96 (m, 3, ArH), 8.12 (d, J = Hz, 1, ArH), 8.68 (s, 1, ArH); EI-HRMS calculated for C$_{28}$H$_{28}$O$_3$, 412.2038; found, 412.2030.

2-(4-Carboxyphenyl)-6,7,8,9-tetrahydro-6,6,9,9-tetramethylbenzo[g]quinoline-1-oxide (SR11365) was prepared by acetylation (Ac$_2$O, Et$_3$N, EtOAc, 25°C; 100%) of 5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-amine to the amide, which on reaction with excess Vilsmeier reagent {[POC]$_3$, 8.5 equivalents; alerts dimethylformamide (DMF) 3.5 equivalents; alerts (CH$_2$Cl)$_2$, 0°C]; 25 to 85°C; aqueous NaHCO$_3$; 61%} produced 2-chloro-6,7,8,9-tetrahydro-6,6,9,9-tetramethylbenzo[g]quinoline-3-carboxaldehyde, which on coupling {Pd[P(C$_6$H$_5$)$_3$]$_4$, NaHCO$_3$, aqueous DME, 80°C; 71%} with 4-carbethoxyphenylboronic acid yielded ethyl 4-[3-formyl-6,7,8,9-tetrahydro-6,6,9,9-tetramethylbenzo-[g]quinolin-2-yl]benzoate. Oxidation of the formyl group to the carboxylic acid with concomitant base hydrolysis of the ester (Ag$_2$O, NaOH, aqueous EtOH-THF, 25°C; H$_3$O$^+$; 100%) gave the dicarboxylic acid, which on thermal decarboxylation (315°C; 93%) yielded 4-[6,7,8,9-tetrahydro-6,6,9,9-tetramethylbenzo-(g)quinolin-2-yl]benzoic acid, which has also been synthesized by another route (26). Esterification (SOCl$_2$, reflux; MeOH-C$_5$H$_5$N-C$_6$H$_5$CH$_3$; aqueous NaHCO$_3$; 91%), N-oxidation (3-ClC$_6$H$_4$CO$_3$H, CHCl$_3$, 25°C; 85%), and ester hydrolysis (NaOH, aqueous EtOH, 70°C; aqueous citric acid; 72%) yielded SR11365: mp, >300°C; ^{1}H NMR (300 MHz, Me$_2$SO-^{2}H$_6$) δ 1.42 (s, 12, CH$_3$), 1.80 (s, 4, CH$_2$), 7.68 (d, J = 9 Hz, 1, ArH), 7.95 (d, J = 9 Hz, 1, ArH), 8.10 (d, J = 8 Hz, 2, ArH), 8.14 (s, 1, ArH), 8.15 (d, J = 8 Hz, 2H, ArH), 8.63 (s, 1, ArH); EI-HRMS calculated for C$_{24}$H$_{25}$NO$_3$, 375.1834; found, 375.1832.

Cell culture. Breast cancer cell lines ZR-75-1, T-47D, and MDA-MB-231 were obtained from the American Type Culture Collection. ZR-75-1 and T-47D cells were grown in RPMI 1640 medium supplemented with 10% fetal calf serum, and MDA-MB-231 and CV-1 cells were grown in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum.

Growth inhibition assay. To study anchorage-dependent growth inhibition, cells were seeded at 500 cells per well in 96-well plates and treated with solvent control (dimethyl sulfoxide-EtOH) or with 10^{-6} M retinoids (or 10^{-7} M trans-RA) in solvent. Media were changed every 48 h. After treatment for 10 days, the number of viable cells were determined by their capacity to convert the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) into a blue formazan product, using a cell proliferation-cytotoxicity assay kit (Promega, Madison, Wis.) (46).

RNA preparation and Northern blot. For Northern blot analysis, total RNAs were prepared by the guanidine hydrochloride-ultracentrifugation method (34). About 30-μg aliquots of total RNAs from different cell lines treated with or without 10^{-6} M retinoids (or 10^{-7} M trans-RA) were fractionated on 1% agarose gel, transferred to nylon filters, and probed with the ^{32}P-labeled ligand-binding domain of receptor cDNAs as previously described (34). To determine that equal amounts of RNA were used, the filters were also probed with β-actin.

Plasmids, receptor proteins, and nuclear extract preparation. The nur77 expression vector was constructed by cloning the nur77 cDNA fragment into pECE or pBluescript vector as described previously (66). The construction of the chloramphenicol acetyltransferase (CAT) reporter containing the RARβ promoter (BglII-BamHI fragment) and expression vectors for RARα, RARβ, and RXRα have been described elsewhere (21, 67, 68). The RXRα N-terminal deletion mutant (ΔRXR10) was constructed by deleting 61 amino acid residues from its N-terminal end as described previously (71). Receptor proteins were synthesized by an in vitro transcription-translation system using rabbit reticulocyte lysate (Promega) as described previously (67). The relative amount of the translated proteins was determined by [^{35}S]methionine-labeled protein on sodium dodecyl sulfate-polyacrylamide gels by quantitating and then normalizing the amount of incorporated radioactivity relative to the content of methionine in each protein. Nuclear extracts were prepared as previously described (34).

TABLE 1. Retinoid transcriptional activation activity

Retinoid	Relative receptor transactivation (%)[a]			
	RARα	RARβ	RARγ	RXRα
trans-RA	100	100	100	53
9-cis-RA				100
SR11277	5	149	65	0
SR11278	13	145	67	0
SR11281	59	123	133	0
SR11365	95	56	48	6
SR11383	66	71	16	7
SR11235	3	27	0	51
SR11246	6	12	9	98
SR11237	1	44	0	95
SR11345	0	−6	−12	107

[a] Transcriptional activation in CV-1 cells, using the (TREpal)$_2$-tk-CAT reporter, compared to 1 μM trans-RA for RARs or 1 μM 9-cis-RA for RXRα as 100%.

Gel retardation assay. The gel retardation assay using in vitro-synthesized proteins or nuclear extracts has been described previously (67, 68). When antibodies were used, 1 μl of anti-nur77 (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) or 1 μl of anti-RXR (32) was incubated with receptor protein at room temperature for 30 min prior to the assay.

Transient transfection and CAT assay. To measure transcriptional activation of the RARβ promoter by retinoids, this promoter (BglII-BamHI fragment) was linked to the CAT gene reporter (21). The reporter plasmid and β-galactosidase expression vector (pCH110; Pharmacia) (100 ng each) with or without the RARβ expression vector were transiently transfected into CV-1 cells by the calcium phosphate precipitation method (34). Cells were grown in the presence or absence of 10^{-6} M retinoids or 10^{-7} M trans-RA. Transfection efficiency was normalized to β-galactosidase activity. The data shown are the means of three separate experiments.

Stable transfection. RARα cDNA was cloned into the pRc/CMV expression vector (Invitrogen, San Diego, Calif.) as described elsewhere (34). The resulting recombinant constructs were then stably transfected into MDA-MB-231 breast cancer cells by the calcium phosphate precipitation method and screened by using G418 (Gibco BRL, Grand Island, N.Y.). The levels of exogenous RARα expression were determined by Northern blotting.

Apoptosis analysis. Cells were treated with or without 10^{-6} M retinoids (or 10^{-7} M trans-RA). After 48 h, cells were trypsinized, washed with phosphate-buffered saline (PBS; pH 7.4), and fixed in 1% formaldehyde in PBS. After washing with PBS, cells were resuspended in 70% ice-cold EtOH and immediately stored at −20°C overnight. Cells were then labeled with biotin-16-dUTP by terminal deoxynucleotidyltransferase (TdT) and stained with avidin-fluorescein isothiocyanate (Boehringer, Mannheim, Germany). Fluorescently labeled cells were analyzed using a FACScater-Plus as described previously (34). Representative histograms are shown.

RESULTS

RXR-selective retinoids inhibit the growth and induce the apoptosis of trans-RA-resistant MDA-MB-231 but not trans-RA-sensitive ZR-75-1 cells. Because trans-RA effectively inhibited the growth and induced the apoptosis of trans-RA-sensitive, estrogen-dependent ZR-75-1 breast cancer cells, whereas it had little effect on trans-RA-resistant, estrogen-independent MDA-MB-231 breast cancer cells (34), RAR- and RXR-class selective retinoids (Table 1) were evaluated for the ability to inhibit the growth and induce the apoptosis of these cell lines. At 10^{-6} M, SR11278, SR11281, SR11277, SR11383, and SR11365 activated only the RARs, not RXRα, on the (TREpal)$_2$-tk-CAT reporter construct (67, 68), as determined by transient transfection in CV-1 cells. SR11237, SR11246, and SR11235 activated both RXRα and RARβ, whereas SR11345 activated only RXRα (Table 1). Both breast cancer cell lines were treated for 10 days with 10^{-6} M the indicated class-selective retinoid alone or the combination of RXR-selective SR11345 and a RAR-selective retinoid. Cell viability was determined by the MTT assay. As shown in Fig. 1, the RAR-selective retinoids strongly inhibited ZR-75-1 cell growth (55

FIG. 1. Growth-inhibitory effects of retinoids on *trans*-RA-sensitive, estrogen-dependent ZR-75-1 and *trans*-RA-resistant, estrogen-independent MDA-MB-231 breast cancer cells. Cells (800 cells/well) were seeded in 96-well plates and treated with the indicated retinoids (10^{-6} M) or *trans*-RA (10^{-7} M) alone or in combination for 10 days. The number of viable cells was determined by the MTT assay.

to 75%). In contrast, the RXR-selective retinoids were far less effective inhibitors (8 to 25%) of growth. ZR-75-1 cell growth inhibition by any of the RAR-selective retinoids was only slightly enhanced by the RXR-selective SR11345. Therefore, growth inhibition of *trans*-RA-sensitive ZR-75-1 cells by retinoids is mediated mainly by the RAR pathway, not the RXR pathway, a finding which is consistent with previous observations (34, 55). Interestingly, in MDA-MB-231 cells, RXR-selective SR11237, SR11246, or SR11235 at 10^{-6} M inhibited growth (45 to 50%) more effectively than any RAR-selective retinoid, which was a poor inhibitor (<20%) (Fig. 1). The more RXR-specific retinoid SR11345 was less effective, with only 8% inhibition. However, when it was used together with one of the RAR-selective retinoids, growth inhibition was increased to 40 to 55%. These results indicate that activation of both RAR and RXR signaling pathways is required for effective cancer cell growth inhibition.

We next investigated the apoptosis-inducing effects of RAR-selective SR11365 and *trans*-RA and of RXR-selective SR11246 in ZR-75-1 and MDA-MB-231 cells by the TdT assay (Fig. 2). *trans*-RA at 10^{-7} M and SR11365 at 10^{-6} M significantly induced apoptosis of ZR-75-1 cells, producing 58 and 27% apoptosis, respectively, whereas RXR-selective SR11246 produced only about 5% apoptotic cells (Fig. 2A). About 44% of MDA-MB-231 cells underwent apoptosis on treatment with SR11246, but apoptosis was not significant on treatment with *trans*-RA (4%) or SR11365 (6%) (Fig. 2B). Together, these results demonstrated that RXR-selective retinoids can induce growth inhibition and apoptosis of *trans*-RA-resistant MDA-MB-231 cells, whereas RAR-selective retinoids are more effective in *trans*-RA-sensitive cells.

Induction of RARβ in *trans*-RA-resistant breast cancer cells by RXR-selective retinoids. We previously demonstrated that RARβ expression levels in breast cancer cells correlated with the extent of growth inhibition and apoptosis induction by *trans*-RA (34). To determine whether growth inhibition and apoptosis induction by RXR-selective retinoids in *trans*-RA-resistant MDA-MB-231 cells were also associated with their

induction of RARβ, we compared the effect of RXR-selective retinoids SR11246 and SR11345 and RAR-selective SR11365, as well as the SR11345 and SR11365 combination, on RARβ expression in these cells (Fig. 3). For comparison, *trans*-RA-sensitive ZR-75-1 and T-47D cells were studied. Both *trans*-RA and RAR-selective SR11365, but not RXR-selective SR11246 or SR11345, induced RARβ expression in ZR-75-1 and T-47D cells. However, RXR-selective SR11246 and SR11345 induced RARβ expression in *trans*-RA-resistant MDA-MB-231 cells at a level comparable to that observed with *trans*-RA or SR11365. A further induction of RARβ was observed when MDA-MB-231 cells were treated with both RXR-selective SR11345 and RAR-selective SR11365. These results demonstrate that activation of RXR by RXR-selective retinoids induced RARβ in *trans*-RA-resistant MDA-MB-231 cells, while these retinoids were unable to activate the RXR-pathway for inducing RARβ in *trans*-RA-sensitive ZR-75-1 and T-47D breast cancer cells. Thus, induction of RARβ by RXR-selective retinoids may contribute to the effects of these retinoids on growth inhibition and apoptosis induction in *trans*-RA-resistant MDA-MB-231 cells.

RXR-selective retinoids activate the RARβ promoter through RXR-nur77 heterodimers. RXR ligands can regulate gene expression through RXR homodimers (68) or certain RXR heterodimers, such as RXR-RAR (4, 31), RXR-LXR (63), or RXR-nur77 (15, 49). Regulation of gene expression by RXR-nur77 heterodimers occurs through their binding to DR-5 type RAREs (15, 49). Because the βRARE in the RARβ promoter is a DR-5 type RARE and contains an NBRE (15, 49, 64), we investigated whether induction of RARβ expression in MDA-MB-231 cells (Fig. 3) could be due to apparent activation of RXR-nur77 heterodimers on the βRARE by RXR-selective retinoids. nur77 alone did not show any clear binding to the βRARE under our experimental conditions but in the presence of RXR produced a strong complex, whose binding was largely affected by either anti-RXR or anti-nur77 antibody (Fig. 4A). For a better distinction between RXR-RAR and RXR-nur77 heterodimers, an RXRα mutant with a deletion of

A ZR-75-1

B MDA-MB-231

FIG. 2. Induction of apoptosis by retinoids in *trans*-RA-sensitive, estrogen-dependent ZR-75-1 (A) and *trans*-RA-resistant, estrogen-independent MDA-MB-231 (B) breast cancer cells. Breast cancer cells were grown in the presence of the indicated retinoids at 10^{-6} M or *trans*-RA at 10^{-7} M for 48 h. DNA fragmentation was determined by the TdT assay. Representative histograms show relative apoptotic cell number. FL, fluorescence.

68 amino acid residues from its N-terminal end (71) was used. The deletion did not affect heterodimerization properties of the RXR with RAR or nur77 (data not shown). The binding of the RXR-nur77 heterodimers to the βRARE was comparable to that of the RXR-RAR heterodimers (Fig. 4A). Thus, the unique structure of the βRARE permits binding of both RXR-RAR and RXR-nur77 heterodimers, as previously observed (15, 49). We next carried out transient transfection assays in CV-1 cells, using the RARβ promoter linked to the CAT gene (21) as a reporter. As shown in Fig. 4B, cotransfection of the RXRα expression vector did not induce reporter transcrip-


FIG. 3. Effects of RAR-selective SR11365 and RXR-selective SR11246 and SR11345 on RARβ gene expression in *trans*-RA-sensitive, estrogen-dependent ZR-75-1 and T-47D and *trans*-RA-resistant, estrogen-independent MDA-MB-231 cells. RNAs were prepared from cells treated with 10^{-6} M RXR-selective SR11246 or SR11345, RAR-selective SR11365, or a combination of SR11345 and SR11365 for 24 h and analyzed for RARβ expression by Northern blotting. For comparison, the expression of the β-actin is shown.

tional activity in response to RXR-selective SR11246 or SR11345, a result that suggests that RXR homodimers do not activate the RARβ promoter as previously observed (68). Co-transfection of the nur77 expression vector clearly induced reporter activity in response to these RXR-selective retinoids but not to RAR-selective *trans*-RA or SR11365. When nur77 and RXR expression vectors were cotransfected, a stronger induction of reporter activity was observed when cells were treated with the RXR-selective retinoids but not with *trans*-RA or SR11365. To determine the effect of RARα on RXR-nur77 activity, we cotransfected the RARα expression vector together with RXRα and nur77. Addition of RARα strongly inhibited RXR-selective retinoid-induced reporter activity but significantly enhanced *trans*-RA and SR11365 activity (Fig. 4B). The inhibition of SR11246 and SR11345 activity by RARα is likely due to competition of RARα and nur77 for het-erodimerization with RXR and binding to the βRARE, which suggests that RXR-selective retinoids SR11246 and SR11345 cannot activate RARβ promoter through RXR-RAR hetero-dimers in CV-1 cells.

Competitive binding of RXR-RAR and RXR-nur77 het-erodimers to the βRARE. Our observation that RARα inhib-ited the transactivation activities of RXR-selective SR11246 and SR11345 on the βRARE (Fig. 4B) suggests that RARα may compete with nur77 for heterodimerization with RXR and thus prevent nur77 from binding to the βRARE. We therefore carried out gel retardation assay using the βRARE as a probe (Fig. 5). When RARα protein was added, binding of RXRα-nur77 heterodimers to the βRARE decreased in a RARα dose-dependent manner. Excess amounts of RARα permitted binding of RXRα-RARα heterodimers. Similarly, increasing nur77 protein levels inhibited RXR-RAR heterodimer binding

FIG. 4. Binding and transactivation of nur77-RXRα and RARα-RXRα on the βRARE. (A) Binding of the nur77-RXRα and RXRα-RARα heterodimers to the βRARE. Equal amounts of in vitro-synthesized nur77 and an N-terminally deleted RXRα (see Materials and Methods) alone or combined were incubated with the βRARE probe at room temperature for 10 min. Mixtures were analyzed by gel retardation. Anti-RXR (αRXR), anti-RARα (αRARα), or anti-nur77 (αnur77) was incubated with receptor proteins for 30 min at room temperature before performance of the assay. For a control, receptor proteins were also incubated with preimmune serum (PI). The βRARE probe sequence was GTAGGGTTCACCGAAAGTTCAGTC (the NBRE is in boldface). (B) nur-77-promoted transactivation of RARβ in CV-1 cells. A CAT reporter containing the RARβ promoter (19) was transiently transfected into CV-1 cells with the receptor expression vector RXRα (20 ng), nur77 (100 ng), or RARα (200 ng). After 24 h, cells were treated with the indicated retinoids (10^{-6} M) or trans-RA (10^{-7} M) for 24 h, and CAT activities were determined as described elsewhere (65).

FIG. 5. Competition binding of RXR-RAR and RXR-nur77 heterodimers to the βRARE. To analyze the effect of RARα on RXR-nur77 heterodimer binding to the βRARE, in vitro-synthesized N-terminally deleted RXRα protein (1 μl) was incubated with in vitro-synthesized nur77 (2 μl) in the absence or presence of the indicated amounts (microliters) of in vitro-synthesized RARα protein and analyzed by gel retardation using the βRARE probe. To analyze the effect of nur77 on RXRα/RARα heterodimer binding, in vitro-synthesized RXRα protein (1 μl) was incubated with in vitro-synthesized RARα (2 μl) in the absence or presence of the indicated amounts (μl) of in vitro-synthesized nur77 and analyzed by gel retardation.

independently of the presence of trans-RA. The high RARα levels in ZR-75-1 cells suggest that binding of RXRα-RARα heterodimers to the βRARE may preferentially occur to mediate the effects of RAR-selective ligands, while the low RARα levels in MDA-MB-231 cells suggest that RXR-nur77 heterodimer may be predominantly formed with the βRARE to mediate the inhibitory effects of RXR-selective ligands.

Stable expression of RARα in trans-RA-resistant MDA-MB-231 cells favors the RAR pathway over the RXR pathway. Low levels of RARα in MDA-MB-231 cells should enhance RXR-nur77 heterodimer formation to mediate the effects of RXR-selective retinoids. To determine whether overexpression of RARα would allow RXR-RAR heterodimer formation but inhibit that of RXR-nur77, we stably transfected RARα into

to the βRARE but enhanced RXR-nur77 heterodimer binding. Thus, RARα and nur77 compete for dimerization with RXR and binding to the βRARE. These data suggest that the relative levels of RARα and nur77 regulate binding of RXR-nur77 and RXR-RAR to the βRARE. We therefore determined whether different levels of RARα, RXRα, and nur77 were expressed in trans-RA-sensitive ZR-75-1 and in trans-RA-resistant MDA-MB-231 cells. Consistent with previous observations (34, 51, 54, 55, 60), RARα levels were much higher in ZR-75-1 cells than in MDA-MB-231 cells (Fig. 6). However, RXRα and nur77 were equally expressed in both cell lines

FIG. 6. Expression of RARα, RXRα, and nur77 in trans-RA-sensitive ZR-75-1 and trans-RA-resistant MDA-MB-231 cells. Total RNAs, prepared from cells treated with 10^{-7} M trans-RA for 24 h, were analyzed for the expression of RARα, RXRα, and nur77 by Northern blotting. For comparison, the expression of the β-actin is shown.

A MDA-MB-231/RARα2   MDA-MB-231/RARα4

B MB-231/RARα2   MB-231/RARα4

RARβ

β-actin

FIG. 7. Effect of stable expression of RARα on growth inhibition and RARβ induction by RXR-selective and RAR-selective retinoids in *trans*-RA-resistant MDA-MB-231 cells. (A) RARα modulates sensitivity of MDA-MB-231 cells to RAR-selective and RXR-selective retinoids. Stable clones, expressing introduced RARα, were seeded at 800 cells/well in 96-well plates and treated with the indicated retinoid (10^{-6} M) or *trans*-RA (10^{-7} M) for 10 days. The number of viable cells was determined by the MTT assay. (B) Stable expression of RARα regulates RARβ expression in response to RAR-selective and RXR-selective retinoids in MDA-MB-231 cells. Stable MDA-MB-231 clones expressing high levels of RARα (MB-231/RARα2 and MB-231/RARα4) were treated with the indicated retinoid (10^{-6} M) alone or in combination and analyzed for the expression of RARβ by Northern blotting. The expression of β-actin was used as the control.

this cell line. Two stable clones (MDA-MB-231–RARα2 and MDA-MB-231–RARα4) that expressed high levels of transfected RARα (data not shown) were analyzed for their responses to RAR and RXR class-selective retinoids (Fig. 7A). Compared to their effects in the parental MDA-MB-231 cells (Fig. 1), RAR-selective *trans*-RA at 10^{-7} M and SR11365 at 10^{-6} M were far more potent inhibitors of the stable clones, showing 46 to 62% inhibition, while RXR-selective SR11246, SR11237, and SR11345 were less effective inhibitors, with less than 21% inhibition. We also investigated the effect of RARα on RARβ expression in MDA-MB-231 cells by Northern blotting (Fig. 7B). In contrast to their effects on the parental cells (Fig. 3), RAR-selective *trans*-RA and SR11365 strongly induced RARβ expression in both clones, while RXR-selective retinoids SR11246 and SR11345 did not. These results demonstrate that low RARα expression in MDA-MB-231 cells is responsible for the increased ability of RXR-selective retinoids and the decreased ability of RAR-selective retinoids to induce RARβ expression and growth inhibition. The fact that the extent of growth inhibition and RARβ expression level by these receptor class-selective retinoids in the stable clones were similar to those in *trans*-RA-sensitive ZR-75-1 and T-47D cells (Fig. 1 and 3) suggests that the differential effects of

retinoids on certain *trans*-RA-sensitive and -resistant breast cancer cell lines depend on different levels of RARα expression.

Binding of nuclear proteins from ZR-75-1 and MDA-MB-231 cells to the βRARE. To provide direct evidence that relative levels of RXR, RARα, and nur77 in *trans*-RA-sensitive ZR-75-1 and *trans*-RA-resistant MDA-MB-231 cells allowed different complex formation on the βRARE, we prepared nuclear proteins from ZR-75-1 and MDA-MB-231 cells and analyzed their binding to the βRARE (Fig. 8). Nuclear proteins

**A** ZR-75-1   MDA-MB-231   MB-231/RARα4

B βRARE   ΔβRARE

FIG. 8. βRARE binding activities of nuclear proteins from ZR-75-1, MDA-MB-231, and MDA-MB-231–RARα4 cells. (A) Nuclear proteins from ZR-75-1 (2 μg), MDA-MB-231 (5 μg), and MDA-MB-231–RARα4 (2 μg) cells were analyzed by gel retardation assay using βRARE as a probe. When antibody (designated as in Fig. 4A) was used, it (1 μl) was incubated with nuclear proteins for 30 min at room temperature before performance of the assay. Preimmune serum (PI) was used for control. (B) Comparison of βRARE and ΔβRARE binding of nuclear proteins from ZR-75-1 (2 μg), MDA-MB-231 (2 μg), and MDA-MB-231/RARα4 (2 μg) cells by gel retardation assay. The ΔβRARE probe sequence was GTAGGGTTCACCG**TG**AGTTCAGTC (mutated nucleotides compared to βRARE are indicated in boldface).

from ZR-75-1 cells formed several strong complexes with the βRARE. When they were incubated with anti-RXR antibody, the slowly migrating complexes were inhibited. When anti-RARα antibody was used, some of the slowly migrating complexes were also abolished. However, anti-nur77 antibody did not show any detectable effect on the binding. These data demonstrate that RXR and RARα are mainly responsible for βRARE binding in ZR-75-1 cells. When nuclear proteins from MDA-MB-231 cells were analyzed, we observed weak βRARE binding complexes, which could be inhibited by anti-RXR and anti-nur77 antibodies but not by anti-RARα antibody. Thus, expression of RXR and nur77 in MDA-MB-231 cells (Fig. 6) could contribute to the βRARE binding activities. To determine whether overexpression of RARα in MDA-MB-231 cells could prevent RXR-nur77 binding as we observed by using in vitro-synthesized receptor proteins (Fig. 5), we analyzed the binding of nuclear proteins prepared from MDA-MB-231–RARα4 cells. As shown in Fig. 8A, the nuclear proteins formed a strong complex with the βRARE, which could be completely inhibited by either anti-RXR antibody or anti-RARα antibody but not by anti-nur77 antibody, indicating that overexpression of RARα in MDA-MB-231 cells inhibited RXR-nur77 heterodimer binding and permitted RXR-RAR heterodimer binding. To further determine the nature of the binding complexes from different cell lines, we used a mutated βRARE (ΔβRARE), in which two adenine nucleotides in the spacing region of the βRARE were mutated. The mutations do not affect binding of RXR-RAR heterodimers but abolish RXR-nur77 binding (66) and thereby allow distinction of RXR-RAR heterodimers from RXR-nur77 heterodimers. When nuclear proteins from ZR-75-1, MDA-MB-231, and MDA-MB-231–RARα4 were analyzed on the ΔβRARE, we observed a strong binding of nuclear proteins from ZR-75-1 and MDA-MB-231–RARα4 cells, similar to that observed with the βRARE. In contrast, nuclear proteins from MDA-MB-231 cells did not show any detectable binding on the ΔβRARE, demonstrating that the binding complex that we observed on the βRARE might represent RXR-nur77 heterodimer binding.

DISCUSSION

Breast cancer cell growth inhibition and apoptosis induction by RXR-selective retinoids. Although conventional retinoids show promise in animal models as preventive agents against breast cancer, their anticancer effects appear to be limited to *trans*-RA-sensitive tumors, whereas the more aggressive, estrogen-independent tumors are usually refractory (14, 34, 54, 55, 60). In this study, we demonstrated that several RXR-selective retinoids inhibit the growth and induce the apoptosis of *trans*-RA-resistant MDA-MB-231 cells (Fig. 1), provided that they are also capable of activating the RARs or are used in combination with RAR-selective retinoids. Efficient growth inhibition by RXR-selective retinoids appears to be cell type specific because it was observed in *trans*-RA-resistant MDA-MB-231 cells but not in *trans*-RA-sensitive ZR-75-1 cells (Fig. 1). In ZR-75-1 cells, RAR-selective SR11365 was much more effective than RXR-selective SR11246 in inhibiting the growth and inducing apoptosis (Fig. 1 and 2). Thus, different retinoid signaling pathways preferentially operate in *trans*-RA-sensitive and *trans*-RA-resistant breast cancer cells to mediate retinoid-induced growth inhibition.

Although the RXR pathway is clearly involved in *trans*-RA-resistant MDA-MB-231 breast cancer cell growth inhibition, a clear growth inhibition by RXR-selective retinoids required a longer period of treatment (Fig. 1) than that by RAR-selective

retinoids, which usually inhibit the growth of *trans*-RA-sensitive breast cancer cells over a period of 3 to 4 days of treatment (data not shown). This observation suggests that the effects of RXR-selective retinoids may involve a mechanism different from that utilized by RAR-selective retinoids. We showed that activation of RXR alone was insufficient for growth inhibition and that activation of RAR appeared to be required, as indicated by our observation that RXR-selective SR11237, SR11246, and SR11247, which at 1 μM have the ability to slightly activate the RARβ (Table 1), can significantly inhibit the growth of MDA-MB-231 cells (Fig. 1), whereas the far more RXR-selective SR11345, which activates RXRα comparably to the other RXR-selective retinoids (Table 1), did not significantly inhibit MDA-MB-231 cell growth (Fig. 1). Furthermore, RXR-selective SR11345 and RAR-selective SR11365, which alone were ineffective inhibitors, on combination strongly prevented MDA-MB-231 cell growth (Fig. 1). The biological activities of RXR-selective retinoids have been described in several studies (6, 17, 47). Activation of RXR was reported as essential for inducing apoptosis in HL-60 leukemia cells (47). RXR-selective retinoid LGD1069 effectively inhibited the tumor development in the *N*-nitroso-*N*-methylurea-induced rat mammary tumor model (17). Because of their increased efficacy against malignant, *trans*-RA-resistant, estrogen-independent breast cancer growth, RXR-selective retinoids may be useful for chemoprevention and chemotherapy of breast cancer.

How RXR-selective retinoids inhibit the growth and induce the apoptosis of *trans*-RA-resistant MDA-MB-231 and other cancer cells remains to be fully elucidated. Induction of growth inhibition and apoptosis of breast cancer cells by retinoids may involve different retinoid receptors and different mechanisms, depending on types of retinoids and cell lines (11, 12, 33, 34, 53–55, 60). The effects of *trans*-RA may be mediated by RARα and RARβ (33, 34, 53–55, 60), whereas activation of RARγ may be required for other retinoids, such as 4-HPR (11, 12). Our data presented here suggest that induction of RARβ may be involved. This is consistent with previous observations that RARβ could mediate the growth-inhibitory effect of *trans*-RA in breast cancer cells (33, 34, 53). RARβ was induced by *trans*-RA only in *trans*-RA-sensitive ZR-75-1 and T-47D, not in *trans*-RA-resistant MDA-MB-231, breast cancer cells (34). In addition, introduction of RARβ into RARβ-negative MDA-MB-231 breast cancer cell lines restored *trans*-RA-induced growth inhibition (33, 34, 53), while inhibition of RARβ activity in the RARβ-positive ZR-75-1 cells with an antisense construct abolished growth inhibition by *trans*-RA (34). Furthermore, enhancement of RARβ levels has been found to correlate with senescence in normal mammary epithelial cells (58). In *trans*-RA-sensitive ZR-75-1 and T-47D cells, RARβ expression was strongly induced by RAR-selective *trans*-RA and SR11365, which also inhibited growth and induced apoptosis, whereas RARβ expression was not induced by RXR-selective SR11246 and SR11345, which only poorly inhibited growth and only weakly induced apoptosis (Fig. 3). The fact that RXR-selective retinoids could induce RARβ expression in *trans*-RA-resistant MDA-MB-231 cells (Fig. 3) suggests that induction of RARβ may contribute to their effects on MDA-MB-231 cells. However, because *trans*-RA and SR11365 induced RARβ to levels similar to those induced by RXR-selective retinoids SR11246 and SR11345 in MDA-MB-231 cells (Fig. 3) but were poor growth inhibitors (Fig. 1), mechanisms other than RARβ induction may also be involved.

SR11345 synergized with RAR-selective retinoids to inhibit MDA-MB-231 cell growth (Fig. 1). Such synergism of RAR- and RXR-selective retinoids has recently been observed in the

activation of several RA-responsive genes, including RARβ, during embryonal carcinoma cell differentiation (52) and in NB4 acute promyelocytic leukemia cells (4). The synergism that we observed here may in part arise from induction and activation of RARβ. Growth inhibition of MDA-MB-231 cells may require both induction and activation of RARβ because RXR-specific SR11345 is a much less effective inhibitor than other RXR-selective retinoids (Fig. 1), which also slightly activate RARβ (Table 1). Enhanced induction of RARβ in MDA-MB-231 cells by the combination of RXR-specific SR11345 and RAR-selective SR11365 (Fig. 3) may also contribute to their synergistic growth inhibition.

Regulation of RARβ expression. The βRARE in the RARβ promoter is responsible for regulating RARβ expression by retinoids (10, 21, 57). Our observation in gel shift assays that efficient binding to the βRARE occurred by heterodimerization of RXRα with nur77 or RARα but not by either receptor alone (Fig. 4A) confirms that the βRARE binds both RXR-RAR and RXR-nur77 heterodimers (15, 49). Activation of the βRARE by trans-RA is caused by binding and activation of RAR-RXR heterodimers, in which RXR functions as a silent partner (15, 30, 38), while activation of the βRARE by RXR-selective retinoids occurs on binding of RXR-nur77 heterodimers (15, 49). Cotransfection of RXRα and nur77 strongly activated RARβ promoter activity in response to RXR-selective SR11246 or SR11345 but not to RAR-selective trans-RA or SR11365 (Fig. 4B). Thus, the βRARE can be activated by either a RAR-selective or RXR-selective retinoid signaling pathway through binding of RXR-RAR or RXR-nur77, respectively. This is reminiscent of a previous observation that the βRARE bound strongly to an RXR-containing complex other than RXR-RAR in S91 melanoma cell extracts (56). Because nur77 expression is induced by several growth factors having different signal transduction pathways (20, 39), the binding and activation of the βRARE by nur77 and retinoid receptors will mediate the convergence of retinoid and growth factor signaling pathways.

Activation of the βRARE by the RAR pathway or RXR pathway depends on the breast cancer cell type. In trans-RA-sensitive cell lines such as ZR-75-1 and T-47D, the expression of RARβ was highly induced by RAR-selective retinoids but not by RXR-selective retinoids, whereas in trans-RA-resistant MDA-MB-231 cells, RARβ expression was induced by RXR-selective retinoids (Fig. 3). Because both RXRα and nur77 are well expressed in MDA-MB-231 cells (Fig. 6), induction of RARβ by RXR-selective retinoids is likely mediated by activation of RXR-nur77 heterodimers on the βRARE. This is further supported by our observation that binding of nuclear proteins prepared from MDA-MB-231 cells to the βRARE may represent RXR-nur77 heterodimers (Fig. 8). Such cell-type-specific activation of the βRARE has been observed previously. In CV-1 cells, RXR-selective retinoids did not appreciably transactivate the DR-5 βRARE even in the presence of transfected RAR and RXR (15, 30). However, in P19 or F9 embryonal carcinoma cells, RXR ligands contributed to transcriptional activation of genes containing DR-5 elements (4, 40, 52). The cell-type-specific activation of the βRARE is likely due to the relative levels of nuclear receptors that bind the βRARE and modulate its activity.

Although RXR-selective retinoids could induce RARβ expression in MDA-MB-231 cells, we observed a stronger induction of RARβ when cells were treated with a combination of RAR-selective and RXR-selective retinoids (Fig. 3). The strong induction of RARβ by the combination may be due to the additive effect of RXR-RAR and RXR-nur77 heterodimers, since RAR-selective retinoids by themselves could

also slightly induce RARβ probably due to low levels of RARα expressed in these cells. Recently, it was reported that binding of RAR-selective retinoids to RXR-RAR heterodimers allowed binding and activation of RXR-RAR heterodimers by RXR-selective retinoids (4, 40). Thus, it is also possible that the strong induction of RARβ that we observed by the combination of RAR-selective and RXR-selective retinoids is due to activation of RXR-RAR heterodimers prebound with RAR-selective retinoid.

RARα regulates both RAR and RXR pathways. trans-RA-sensitive and -resistant breast cancer cell lines display different responses to retinoid receptor class-selective ligands. RAR-selective retinoids are potent RARβ inducers and growth inhibitors in trans-RA-sensitive ZR-75-1 cells, while RXR-selective retinoids effectively induce RARβ and inhibit the growth of trans-RA-resistant MDA-MB-231 cells (Fig. 1 and 3). The observation that the βRARE can be activated by either RXR-RAR or RXR-nur77 suggests that the pathway that mediates growth inhibition and RARβ induction may largely depend on the relative levels of RARα, RXRα, and nur77. In lung cancer cell lines, nur77 expression is associated with trans-RA resistance (66) and could be critical in regulating RAR and RXR activities. However, in breast cancer cell lines, ZR-75-1 and MDA-MB-231 cell lines express similar levels of RXRα and nur77, while RARα varies, being highly expressed in the former and underexpressed in the latter (Fig. 6), as has been previously observed (34, 51, 55, 60). Thus, RARα levels appear to be most important for determining whether the RAR or RXR pathway will regulate growth inhibition by retinoids. High RARα levels in trans-RA-sensitive ZR-75-1 cells may permit formation of RXR-RAR heterodimers that bind to the βRARE (Fig. 5 and 8) to mediate the effects of RAR-selective retinoids in inducing RARβ expression and growth inhibition (34) but prevent RXRα from forming RXR-nur77 heterodimers (Fig. 5 and 8) so that RXR-selective retinoids are unable to inhibit growth or induce apoptosis despite the abundant expression of nur77. In contrast, low RARα levels in trans-RA-insensitive MDA-MB-231 cells (Fig. 6) allow formation of RXR-nur77 heterodimers (Fig. 8) that bind to the βRARE to mediate RARβ expression and may be responsible for growth inhibition in the presence of RXR-selective retinoids. The importance of RARα levels in determining the regulatory pathway is supported by our gel retardation (Fig. 5 and 8) and transfection assay results (Fig. 4B). Gel retardation indicates that binding of RXR-RAR or RXR-nur77 heterodimers to the βRARE largely depends on RARα protein levels (Fig. 5 and 8). Overexpression of RARα in MDA-MB-231 cells allowed binding of RXR-RARα heterodimers and prevented binding of RXR-nur77 heterodimers to the βRARE (Fig. 5 and 8). In transient transfection assays, cotransfection of RARα inhibited RXR-selective retinoid-induced RXR-nur77 heterodimer activity on the RARβ promoter (Fig. 4B). Furthermore, stable expression of RARα in MDA-MB-231 cells strongly enhanced growth inhibition (Fig. 7A) and RARβ induction (Fig. 7B) by RAR-selective retinoids and decreased the inhibitory effects of RXR-selective retinoids. Thus, high RARα levels favor formation of RAR-RXR heterodimers and the RAR signaling pathway in breast cancer cells, while low RARα levels favor the formation of nur77-RXR heterodimers and the RXR signaling pathway. This retinoid signaling switch may play an important role in regulating breast cancer cell growth in response to different growth factor and retinoid stimuli.

In summary, we have demonstrated that RXR-selective retinoids inhibit the growth and induce the apoptosis of trans-RA-resistant MDA-MB-231 breast cancer cells, which appears to

be mediated through RXR-nur77 heterodimers that bind and activate the βRARE in the presence of RXR-selective retinoids, resulting in induction of RARβ, which may then be activated by RAR-selective retinoids to initiate secondary biological responses. RXR-nur77 heterodimer formation in *trans*-RA-resistant MDA-MB-231 cells is favored by very low RARα levels, whereas high expression of RARα in *trans*-RA-sensitive ZR-75-1 cells favors formation of RXR-RAR heterodimers that bind and activate the βRARE in response to RAR-selective ligands. Thus, the convergence and switch of RAR-dependent and RXR-dependent signaling on the βRARE is very likely regulated by relative RARα levels. Our findings that an RXR signaling pathway can mediate growth inhibition and apoptosis induction and the additive to synergistic effects of a RAR-selective and RXR-selective retinoid combination on *trans*-RA-resistant MDA-MB-231 cell growth may provide a therapeutic opportunity to inhibit the growth of more invasive, *trans*-RA-resistant breast cancer by using lower retinoid doses to reduce toxicity.

REFERENCES

1. Bartsch, D., B. Boye, C. Baust, H. zur Hausen, and E. Schwarz. 1992. Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor β gene in nontumorigenic and tumorigenic HeLa hybrid cells. EMBO J. 11:2283–2291.
2. Boccardo, F., L. Canobbio, M. Resasco, A. U. Decensi, G. Pastorino, and F. Brema. 1990. Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. J. Cancer Res. Clin. Oncol. 116:503–506.
3. Cassidy, J., M. Lippman, A. Lacroix, and G. Peck. 1982. Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur. J. Cancer Clin. Oncol. 18:925–928.
4. Chen, J.-Y., J. Clifford, C. Zusi, J. Starrett, D. Tortolani, J. Ostrowski, P. R. Reczek, P. Chambon, and H. Gronemeyer. 1996. Two distinct actions of retinoid-receptor ligands. Nature 382:819–822.
5. Clifford, J. L., M. Petkovich, P. Chambon, and R. Lotan. 1990. Modulation by retinoids of mRNA levels for nuclear retinoic acid receptors in murine melanoma cells. Mol. Endocrinol. 4:1546–1555.
6. Davis, K. D., T. J. Berrodin, J. E. Stelmach, J. D. Winkler, and M. A. Lazar. 1994. Endogenous retinoid X receptors can function as hormone receptors in pituitary cells. Mol. Cell. Biol. 14:7105–7110.
7. Dawson, M. I., W. R. Chao, P. Ping, L. Jong, P. D. Hobbs, C. Rudd, T. C. Quick, R. M. Niles, X.-K. Zhang, A. Lombardo, K. R. Ely, B. Shroot, and J. A. Fontana. 1995. Correlation of retinoid binding affinity to RARα with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res. 55:4446–4451.
8. Dawson, M. I., L. Jong, P. D. Hobbs, J. F. Cameron, W. R. Chao, M. Pfahl, M. O. Lee, and B. Shroot. 1995. Conformational effects on retinoid receptor selectivity. 2. Effects of retinoid bridging group on retinoid X receptor activity and selectivity. J. Med. Chem. 38:3368–3383.
9. Dejean, A., L. Bougueleret, K.-H. Grzeschik, and P. Tiollais. 1986. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 322:70–72.
10. de The, H., M. del Mar Vivanco-Ruiz, P. Tiollais, H. Stunnenberg, and A. Dejean. 1990. Identification of a retinoic acid responsive element in the retinoic acid receptor β gene. Nature 343:177–180.
11. Fanjul, A. N., D. Delia, M. A. Pierotti, D. Rideout, J. Qiu, and M. Pfahl. 1996. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J. Biol. Chem. 271:22441–22446.
12. Fanjul, A. N., H. Bouterfa, M. Dawson, and M. Pfahl. 1996. Potential role for retinoic acid receptor-γ in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res. 56:1571–1577.
13. Fontana, J. A. 1987. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp. Cell. Biol. 55:136–144.
14. Fontana, J. A., P. D. Hobbs, and M. I. Dawson. 1988. Inhibition of mammary carcinoma growth by retinoidal benzoic acid derivatives. Exp. Cell. Biol. 56:254–263.
15. Forman, B. M., K. Umesono, J. Chen, and R. M. Evans. 1995. Unique response pathways are established by allosteric interactions among receptors. Cell 81:541–550.
16. Gebert, J. F., N. Moghal, J. V. Frangioni, D. J. Sugarbaker, and B. G. Neel. 1991. High frequency of retinoic acid receptor β abnormalities in human lung cancer. Oncogene 6:1859–1868.
16a. Giuseppe, G., M. I. Dawson, X.-K. Zhang, C. J. Thiele. Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells. J. Biol. Chem., in press.
17. Gottardis, M. M., E. D. Bischoff, M. A. Shirley, M. A. Wagoner, W. W. Lamph, and R. A. Heyman. 1996. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 56:5566–5570.
18. Grubbs, C. J., R. C. Moon, M. B. Sporn, and D. L. Newton. 1977. Inhibition of mammary cancer by retinyl methyl ether. Cancer Res. 37:599–602.
19. Gudas, L. J., M. B. Sporn, and A. B. Roberts. 1994. Cellular biology and biochemistry of the retinoids, p. 443–520. In M. B. Sporn, A. B. Roberts, and D. S. Goodman (ed.), The retinoids. Raven Press, New York, N.Y.
20. Hazel, T. G., D. Nathans, and L. F. Lau. 1988. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc. Natl. Acad. Sci. USA 85:8444–8448.
21. Hoffmann, B., J. M. Lehmann, X.-K. Zhang, T. Hermann, G. Graupner, and M. Pfahl. 1990. A retinoic acid receptor-specific element controls the retinoic acid receptor-β promoter. Mol. Endocrinol. 4:1734–1743.
22. Houle, B., F. Ledue, and W. E. C. Bradley. 1991. Implication of RARβ in epidermoid (squamous) carcinoma cells. Exp. Cell Res. 195:163–170.
23. Houle, B., C. Rochette-Egly, and W. E. C. Bradley. 1993. Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. USA 90:985–989.
24. Hu, L., D. L. Crowe, J. G. Rheinwald, P. Chambon, and L. Gudas. 1991. Abnormal expression of retinoic acid receptors and keratin 19 by human oral and epidermal squamous cell carcinoma cell lines. Cancer Res. 51:3972–3981.
25. Kagechika, H., E. Kawachi, Y. Hashimoto, T. Himi, and K. Shudo. 1988. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J. Med. Chem. 31:2182–2192.
26. Kagechika, H., E. Kawachi, G. Saito, H. Fukusawa, Y. Hashimoto, and K. Shudo. 1995. Comparison of differentiation between NB4 and HL-60 cells induced by retinoids, abstr. B-27. In Abstracts of mechanisms of action of retinoids, vitamin D, and steroid hormones. AACR Special Conference, British Columbia, Canada.
27. Kamei, Y., L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S.-C. Lin, R. A. Heyman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld. 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403–414.
28. Kastner, P., M. Mark, and P. Chambon. 1995. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83:859–869.
29. Koga, M., and R. L. Sutherland. 1991. Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D_3 or antiestrogen to inhibit T-47D human breast cancer cell proliferation. J. Steroid Biochem. Mol. Biol. 39:455–460.
30. Kurokawa, R., J. DiRenzo, M. Boehm, J. Sugarman, B. Gloss, M. G. Rosenfeld, R. A. Heyman, and C. K. Glass. 1994. Regulation of retinoid signalling by receptor polarity and allosteric binding. Nature 371:528–531.
31. Lala, D. S., R. Mukherjee, I. G. Schulman, S. S. Canan Koch, L. J. Dardashti, A. M. Nadzan, G. E. Croston, R. M. Evans, and R. A. Heyman. 1996. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383:450–453.
32. Lee, M.-O., Y. Liu, and X.-K. Zhang. 1995. A retinoic acid response element that overlaps an estrogen response element mediates multihormonal sensitivity in transcriptional activation of the lactoferrin gene. Mol. Cell. Biol. 15:4194–4207.
33. Li, X.-S., Z.-M. Shao, M. H. Shekh, J. L. Eiseman, D. Sentz, A. M. Jetten, J.-H. Chen, M. I. Dawson, S. Aisner, A. K. Rishi, P. Gutierrez, L. Schnapper, and J. A. Fontana. 1995. Retinoic acid nuclear receptor β inhibits breast carcinoma anchorage independent growth. J. Cell. Physiol. 165:449–458.
34. Liu, Y., M.-O. Lee, H.-G. Wang, Y. Li, Y. Hashimoto, M. Klaus, J. C. Reed, and X.-K. Zhang. 1996. RARβ mediates the growth inhibitory effect of retinoic acid by inducing cell apoptosis in human breast cancer cells. Mol. Cell. Biol. 16:1138–1149.
35. Liu, Z.-G., S. W. Smith, K. A. McLaughlin, L. M. Schwartz, and B. A. Osborne. 1994. Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature 367:281–284.
36. Lotan, R. 1981. Effect of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim. Biophys. Acta 605:33–91.
37. Lotan, R., X. C. Xu, S. M. Lippman, J. Y. Ro, J. S. Lee, J. J. Lee, and W. K. Hong. 1995. Suppression of retinoic acid receptor-β in premalignant oral

lesions and its upregulation by isotretinoin. N. Engl. J. Med. **332:**1405–1410.

38. **Mangelsdorf, D. J., and R. M. Evans.** 1995. The RXR heterodimers and orphan receptors. Cell **83:**841–850.

39. **Milbrandt, J.** 1988. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. Neuron **1:**183–188.

40. **Minucci, S., M. Leid, R. Toyama, J.-P. Saint-Jeannet, V. J. Peterson, V. Horn, J. E. Ishmael, N. Bhattacharyya, A. Dey, I. B. Dawid, and K. Ozato.** 1997. Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid-dependent gene expression. Mol. Cell. Biol. **17:**644–655.

41. **Miyaura, N., and A. Suzuki.** 1995. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. **95:**2457–2483.

42. **Modiano, M., W. Dalton, S. Lippman, L. Joffe, A. R. Booth, and F. L. Meyskens, Jr.** 1990. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest. New Drugs **8:**317–319.

43. **Moon, R. C., and R. G. Mehta.** 1990. Chemoprevention of mammary cancer by retinoids. Basic Life Sci. **52:**213–224.

44. **Moon, R. C., J. F. Pritchard, R. G. Mehta, C. T. Monides, C. F. Thomas, and N. M. Dinger.** 1989. Suppression of rat mammary cancer development by *N*-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis **10:**1645–1649.

45. **Moon, R. C., H. J. Thompson, P. J. Becci, C. J. Grubbs, R. J. Gander, D. L. Newton, J. M. Smith, S. L. Phillips, W. R. Henderson, L. T. Mullen, C. C. Brown, and M. B. Sporn.** 1979. *N*-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. **39:**1339–1346.

46. **Mosmann, T.** 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods **65:**55–63.

47. **Nagy, L., V. A. Thomazy, G. L. Shipley, L. Fesus, W. Lamph, R. A. Heyman, R. A. Chandraratna, and P. J. Davies.** 1995. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol. Cell. Biol. **15:**3540–3551.

48. **Nervi, C., T. M. Volleberg, M. D. George, A. Zelent, P. Chambon, and A. M. Jetten.** 1991. Expression of nuclear retinoic acid receptors in normal tracheobronchial cells and in lung carcinoma cells. Exp. Cell Res. **195:**163–170.

49. **Perlmann, T., and L. Jansson.** 1995. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and Nurr1. Genes Dev. **9:**769–782.

50. **Roberts, A. B., and M. B. Sporn.** 1984. Cellular biology and biochemistry of the retinoids, p. 209–286. *In* M. B. Sporn, A. B. Roberts, and D. S. Goodman (ed.), The retinoids. Academic Press, Orlando, Fla.

51. **Roman, S. D., C. L. Clarke, R. E. Hall, I. E. Alexander, and R. L. Sutherland.** 1992. Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res. **52:**2236–2242.

52. **Roy, B., R. Taneja, and P. Chambon.** 1995. Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor α (RARα)-, RARβ-, or RARγ-selective ligand in combination with a retinoid X receptor-specific ligand. Mol. Cell. Biol. **15:**6481–6487.

53. **Seewaldt, V. L., B. S. Johnson, M. B. Parker, S. J. Collins, and K. Swisshelm.** 1995. Expression of retinoic acid receptor β mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. **6:**1077–1088.

54. **Sheikh, M. S., Z. M. Shao, J. C. Chen, A. Hussain, A. M. Jetten, and J. A. Fontana.** 1993. Estrogen receptor-negative breast cancer cells transfected with the estrogen receptor exhibit increased RARα gene expression and sensitivity to growth inhibition by retinoic acid. J. Cell. Biochem. **53:**394–404.

55. **Sheikh, M. S., Z. M. Shao, X. S. Li, M. Dawson, A. M. Jetten, S. Wu, B. A. Conley, M. Garcia, H. Rochefort, and J. A. Fontana.** 1994. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with

retinoic acid receptor-α acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem. **269:**21440–21447.

56. **Spanjaard, R. A., A. Sugawara, M. Ikeda, and W. W. Chin.** 1995. Evidence that retinoid X receptors mediate retinoid-dependent transcriptional activation of the retinoic acid receptor β gene in S91 melanoma cells. J. Biol. Chem. **270:**17429–17436.

57. **Sucov, H. M., K. K. Murakami, and R. M. Evans.** 1990. Characterization of an autoregulated response element in the mouse retinoic acid receptor type β gene. Proc. Natl. Acad. Sci. USA **87:**5392–5396.

58. **Swisshelm, K., K. Ryan, X. Lee, H. C. Taou, M. Peacocke, and R. Sager.** 1994. Down-regulation of retinoic acid receptor β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ. **5:**133–141.

59. **Taneja, R., B. Roy, J.-L. Plassat, C. F. Zusi, J. Ostrowski, P. R. Reczek, and P. Chambon.** 1996. Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for *RAR*β2 and *Hoxa-1* activation in F9 and P19 cells can be artefactually generated by gene knockouts. Proc. Natl. Acad. Sci. USA **93:**6197–6202.

60. **van der Burg, B., B.-J. M. van der Leede, L. Kwakkenbos-Isbrucker, S. Salverda, S. W. de Laat, and P. T. van der Saag.** 1993. Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function. Mol. Cell. Endocrinol. **91:**149–157.

61. **van der Leede, B. J., G. E. Folkers, C. E. van den Brink, P. T. van der Saag, and B. van der Burg.** 1995. Retinoic acid receptor α isoform is induced by estradiol and confers retinoic acid sensitivity in human breast cancer cells. Mol. Cell. Endocrinol. **109:**77–86.

62. **Wetherall, N. T., and C. M. Taylor.** 1986. The effects of retinoid treatment and antiestrogens on the growth of T47D human breast cancer cells. Eur. J. Cancer Clin. Oncol. **22:**53–59.

63. **Willy, P. J., K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, and D. J. Mangelsdorf.** 1995. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. **9:**1033–1045.

64. **Wilson, T. E., T. J. Fahrner, M. Johnston, and J. Milbrandt.** 1991. Identification of the DNA binding site for NGFI-B by genetic selection in yeast. Science **252:**1296–1300.

65. **Woronicz, J. D., B. Cainan, V. Ngo, and A. Winoto.** 1994. Requirement for the orphan steroid receptor nur77 in apoptosis of T-cell hybridomas. Nature **367:**277–281.

66. **Wu, Q., Y. Li, R. Liu, A. Agadir, M.-O. Lee, Y. Liu, and X.-K. Zhang.** 1997. Modulation of retinoic acid sensitivity in lung cancer cells by a dynamic balance of nur77 and COUP-TF orphan receptors and their heterodimerization. EMBO J. **16:**1656–1669.

67. **Zhang, X.-K., B. Hoffmann, P. B. Tran, G. Graupner, and M. Pfahl.** 1992. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature **355:**441–446.

68. **Zhang, X.-K., J. Lehmann, B. Hoffmann, M. I. Dawson, J. Cameron, G. Graupner, T. Hermann, P. Tran, and M. Pfahl.** 1992. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid. Nature **358:**587–591.

69. **Zhang, X.-K., Y. Liu, M. O. Lee, and M. Pfahl.** 1994. A specific defect in the retinoic acid receptor associated with human lung cancer cell lines. Cancer Res. **54:**5663–5669.

70. **Zhang, X.-K., and M. Pfahl.** 1993. Hetero- and homodimeric receptors in thyroid hormone and vitamin A action. Receptor **3:**183–191.

71. **Zhang, X-K., G. Salbert, M.-O. Lee, and M. Pfahl.** 1994. Mutations that alter ligand-induced switches and dimerization activities in the retinoid X receptor. Mol. Cell. Biol. **14:**4311–4323.

72. **Zhao, Z., Z. P. Zhang, D. R. Soprano, and K. J. Soprano.** 1995. Effect of 9-cis-retinoic acid on growth and RXR expression in human breast cancer cells. Exp. Cell Res. **219:**555–561.

Interaction of BAG-1 with Retinoic Acid Receptor and Its Inhibition of Retinoic Acid-induced Apoptosis in Cancer Cells*

Ru Liu, Shinichi Takayama, Yun Zheng, Barbara Froesch, Guo-quan Chen, Xin Zhang, John C. Reed, and Xiao-kun Zhang‡

From The Burnham Institute, Cancer Research Center, La Jolla, California 92037

BAG-1 (also known as RAP46) is an anti-apoptotic protein, which has been shown previously to interact with a number of nuclear hormone receptors, including receptors for glucocorticoid, estrogen, and thyroid hormone. We show here that BAG-1 also interacts with retinoic acid receptor (RAR). Gel retardation assays demonstrated that *in vitro* translated BAG-1 protein could effectively inhibit the binding of RAR but not retinoid X receptor (RXR) to a number of retinoic acid (RA) response elements (RAREs). A glutathione *S*-transferase-BAG-1 fusion protein also specifically bound RAR but not RXR. Interaction of BAG-1 and RAR could also be demonstrated by yeast two-hybrid assays. In transient transfection assays, co-transfection of BAG-1 expression plasmid inhibited the transactivation activity of RAR/RXR heterodimers but not RXR/RXR homodimers. When stably expressed in breast cancer cell lines, BAG-1 inhibited binding of RAR/RXR heterodimer to a number of RAREs and suppressed RA-induced growth inhibition and apoptosis. In addition, RA-induced suppression of Bcl-2 expression was abrogated by overexpression of BAG-1. These results demonstrate that BAG-1 can regulate retinoid activities through its interaction with RAR and suggest that elevated levels of BAG-1 protein could potentially contribute to retinoid resistance in cancer cells.

Development of a multicellular organism requires tightly regulated cellular processes, such as proliferation, differentiation, and cell death. Failure to maintain the balance among these fundamental and mechanistically related processes may result in abnormal cell growth, as seen in cancer cells where cell death is often inhibited (1, 2). Retinoids, a group of natural and synthetic vitamin A derivatives, are currently used to treat epithelial cancer and promyelocytic leukemia and are being evaluated for prevention and therapy of other human cancers (3, 4). The anti-cancer effects of retinoids are mainly due to their inhibition of cell proliferation, induction of cell differentiation, and promotion of apoptosis. Retinoids alone or in combination with other stimuli induce apoptosis during normal development and in different types of cancer cells *in vitro*

(5–11). However, it remains largely unknown how retinoid-induced apoptosis is regulated.

The effects of retinoids are mainly mediated by two classes of nuclear receptors, the retinoic acid receptors (RARs)[1] and retinoid X receptors (RXRs). RARs and RXRs are encoded by three distinct genes (α, β, and γ) and are members of the steroid/thyroid/retinoid hormone receptor superfamily that function as ligand-activated transcription factors (12–14). 9-*cis* RA is a high affinity ligand for both RARs and RXRs, whereas all-*trans*-RA (*trans*-RA) is a ligand for only RARs. RARs and RXRs primarily function as RXR/RAR heterodimers that bind to a variety of RA response elements (RAREs) and regulate their transactivation activities.

Regulation of gene expression either positively or negatively by nuclear hormone receptors is modulated by additional factors. Some of them appear to provide a direct link to the core transcriptional machinery and to modulate chromatin structure (15), such as SRC-1 (16), SUG-1 (17), TIF-1 (18), RIP-140 (19), N-CoR (25), SMRT (26), TIF-2 (20), GRIP-1 (21), p160 (22), CBP (23), AIB1 (8), and ACTR (24), whereas a number of other cellular proteins, such as AP-1, have been implicated in the regulation of nuclear hormone receptor activity, probably through their interaction with receptors (27).

The involvement of retinoid receptors in retinoid-induced apoptosis has been demonstrated in several studies. Expression of RARβ may be involved in the apoptosis of mesenchyme of the interdigital regions during mouse limb development (28). RARβ is required for RA-induced apoptosis of breast cancer (5) and lung cancer (7) cells, whereas activation of RXR is essential for RA-induced HL-60 cell apoptosis (29). In 4-HPR-induced apoptosis, activation of RARγ may be involved (30, 31), whereas regulation of activation-induced apoptosis of T-cells by 9-*cis* RA requires activation of both RARs and RXRs (32).

Although much interest has been directed to the role of retinoid-induced apoptosis in both physiological and pathological processes, very little is known regarding regulation of the process. It is believed that apoptosis, once triggered, proceeds through a central death pathway in which specific cellular proteases and endonucleases are activated (1, 2, 33). Members of the Bcl-2 family play an important role in the regulation of the central death pathway. Bcl-2 can suppress induction of apoptosis in many systems, whereas Bax promotes apoptosis. In addition, several other proteins that modulate Bcl-2 activity by interacting with Bcl-2 have been described (1, 2, 33). One of these genes, *BAG-1* (for Bcl-2-associated anti-death gene 1), was cloned from a murine embryo cDNA library using a pro-

[1] The abbreviations used are: RAR, retinoic acid receptor; RXR, retinoid X receptor; RARE, retinoic acid response elements; TR, thyroid hormone receptor; MTT, 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; GST, glutathione *S*-transferase; tk, thymidine kinase; MHC, myosin heavy chain; CAT, chloramphenicol acetyltransferase.

Interaction of BAG-1 with Retinoic Acid Receptor

tein-protein interaction technique (34). Two differently localized BAG-1 isoforms, the long BAG-1 isoform and the short BAG-1 isoform, generated by alternative translation initiation are expressed in mammalian cells (35). Whether two isoforms act differently remains to be determined. Recent studies demonstrated that co-expression of BAG-1 and Bcl-2 in Jurkat lymphoid cells, NIH 3T3 fibroblasts, and melanoma cells promoted the survival of these cells in response to a variety of apoptotic stimuli (34, 36, 37). In addition to Bcl-2, BAG-1 also interacts with Raf-1 (38), resulting in activation of its kinase activity. Furthermore, BAG-1 can interact with hepatocyte growth factor receptor and platelet-derived growth factor receptor and enhance the ability of these receptors to transduce signals for cell survival (39). These observations suggest that BAG-1 may function as an adaptor to mediate the interaction between survival factors and apoptotic machinery and may also play a role in regulating cellular proliferation. The recent observation that BAG-1 binds tightly to Hsp70/Hsc70-family proteins and modulates their chaperone activity (40–42) suggests that the ability of BAG-1 to alter the activities of diverse groups of proteins involved in cell growth control may be attributed to its effects on Hsp70/Hsc70 proteins.

Interestingly, the human BAG-1 homolog (also known as RAP46) was cloned from a human liver cDNA library by virtue of its interaction with the glucocorticoid receptor (43). *In vitro*, RAP46 interacts with a number of nuclear hormone receptors, including estrogen receptor and thyroid hormone receptor (TR) (43). Since molecular chaperones are known to play an important role in controlling the activity of many members of the steroid/thyroid/retinoid receptor family (44), it is possible that BAG-1 could alter the function of these transcriptional regulators. Before this report, however, it was unknown whether BAG-1 regulates the activities of the nuclear hormone receptors and whether BAG-1 interacts with retinoid receptors.

Here we demonstrate that short BAG-1 isoform interacts with the RAR but not the RXR both *in vitro* and *in vivo*. GST pull-down and the yeast two-hybrid assays show that BAG-1 directly interacts with RAR but not RXR. Moreover, BAG-1 inhibits RAR/RXR heterodimer DNA binding and suppresses RA-induced transactivation activity of RARs on various RAREs. Overexpression of BAG-1 in MCF-7 and ZR-75-1 breast cancer cells reduces the ability of *trans*-RA to inhibit the growth and induce apoptosis, as well as its modulation of Bcl-2 expression. Taken together, our results demonstrate that BAG-1 can physically interact with RARs and is an important component in the retinoid response pathway. Our findings suggest that this protein-protein interaction may play a role in the regulation of retinoid-induced growth inhibition and apoptotic processes, potentially contributing to retinoid resistance in cancer.

MATERIALS AND METHODS

Cell Culture—Monkey kidney CV-1 cells and breast cancer MCF-7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, and ZR-75-1 breast cancer cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum.

Growth Inhibition Assay—Cells were seeded at 1,000–2,000 cells/well in 96-well plates and treated 24 h later with various concentrations of *trans*-RA for 7 days. Media and *trans*-RA were changed every 48 h. Relative viable cell number was determined using the MTT assay (52).

Apoptosis Analysis—For the terminal deoxynucleotidyl transferase assay (5), cells were treated with or without 10^{-6} M *trans*-RA. After 48 h, cells were trypsinized, washed with phosphate-buffered saline, fixed in 1% formaldehyde in phosphate-buffered saline, washed with phosphate-buffered saline, resuspended in 70% ice-cold ethanol, and stored at −20 °C overnight. Cells were then labeled with biotin-16-dUTP by terminal transferase and stained with avidin-fluorescein isothiocyanate (Boehringer Mannheim). Fluorescently labeled cells were analyzed using a FACScater-Plus. Representative histograms are

FIG. 1. **Inhibition of RAR DNA binding by BAG-1.** *a*, inhibition of RAR/RXR heterodimer binding by BAG-1. *In vitro* synthesized RARα and RXRα were preincubated with the indicated molar excess of *in vitro* synthesized BAG-1 or estrogen receptor (*ER*). Unprogrammed reticulocyte lysate was used to maintain an equal protein concentration in each reaction. After this preincubation, the reaction mixtures were incubated with ^{32}P-labeled TREpal and analyzed by the gel retardation assay. The *open arrow* indicates nonspecific binding. *b*, inhibition of TRα/RXRα binding by BAG-1. *In vitro* synthesized TRα and RXRα were preincubated with the indicated molar excess amount of *in vitro* synthesized BAG-1 and analyzed by the gel retardation assay using the TREpal as a probe. *c*, inhibition of RARα/RXRα binding on the βRARE by BAG-1. *In vitro* synthesized RARα and RXRα were preincubated with the indicated molar excess amount of *in vitro* synthesized BAG-1 and analyzed by the gel retardation assay using the β RARE as a probe. *d*, inhibition of DNA binding of bacterially expressed RAR but not RXR by BAG-1. Bacterially expressed RARγ or RXRα protein was preincubated with 6 µl of *in vitro* synthesized BAG-1 and analyzed by the gel retardation assay using the TREpal as a probe.

shown.

Antibodies and Immunoblotting—Cells were lysed in 150 mM NaCl, 10 mM Tris, pH7.4, 5 mM EDTA, 1% Triton X-100 and protease inhibitors phenylmethylsulfonyl fluoride, aprotinin, leupeptins, and pepstatin. Equal amounts of lysates (50 µg) were boiled in SDS sample buffer, resolved by SDS-polyacrylamide gel electrophoresis, and transferred onto nitrocellulose membrane. After transfer, the membranes were blocked in TBST (50 mM Tris, pH7.5, 150 mM NaCl, 0.1% Tween 20) containing rabbit anti-Bcl-2 serum. The membranes were then washed

FIG. 2. **Analysis of RAR-BAG-1 interaction by the GST pull-down assay.** BAG-1 or a BAG-1 C-terminal deletion mutant (BAG-1/Δc) was expressed in bacteria using the pGex.4T expression vector. The GST-BAG-1 proteins were immobilized on glutathione-Sepharose beads. As a control, the same amount of GST was also immobilized. ^{35}S-Labeled RARα, RXRα, or Bcl-2 was then mixed with the beads. After extensive washing, the bound proteins were analyzed by SDS-polyacrylamide gel electrophoresis. The input proteins are shown for comparison (*left panel*). For comparison, binding of GST-BAG-1 and GST-BAG-1/Δc to Hsc70 was shown in *right panel*.

three times with TBST and then incubated for 1 h at room temperature in TBST containing horseradish peroxidase-linked anti-rabbit immunoglobulin. After three washes in TBST, immunoreactive products were detected by chemiluminescence with an enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech).

Transient and Stable Transfection Assay—For CV-1 cells, 1×10^5 cells were plated per well in a 24-well plates 16–24 h before transfection as described previously (45). For ZR-75-1 cells, 5×10^5 cells/well were seeded in 6-well culture plates. A modified calcium phosphate precipitation procedure was used for transient transfection (45). For CV-1 cells, 100 ng of reporter plasmid, 150 ng of β-galactosidase expression vector (pCH 110, Amersham), and various amounts of BAG-1 expression vector that expresses short BAG-1 isoform (35) were mixed with carrier DNA (pBluescript) to 1,000 ng of total DNA/well. Reporter plasmids βRARE-tk-CAT, TREpal-tk-CAT, and TRE$_{MHC}$-tk-CAT have been previously described (45–48). For stable transfection, the pRc/CMV-BAG-1 plasmid (34) that expresses short BAG-1 isoform was stably transfected into MCF-7 or ZR-75-1 cells using calcium phosphate precipitation method, followed by selection using G418 (Life Technologies, Inc.) as described (5).

Preparation of Receptor, BAG-1, and Nuclear Protein—cDNAs for RARα, RXRα, estrogen receptor, and BAG-1, which expresses short BAG-1 isoform cloned into pBluescript (Stratagene), were transcribed by using T$_7$ or T$_3$ RNA polymerase, and the transcripts were translated in the rabbit reticulocyte lysate system (Promega) as described previously (45). The relative amounts of the translated proteins were determined by separating the [^{35}S]methionine-labeled proteins on SDS-polyacrylamide gels, quantitating the amount of incorporated radioactivity and normalizing it relative to the content of methionine residues in each protein. To synthesize receptor fusion protein, RARγ or RXRα cDNAs were cloned in-frame into the bacterial expression vector pGex.2T (Amersham) as described (45). Preparation and purification of GST-BAG-1 and GST-BAG-1(Δ172–218) fusion proteins has been described (41). Preparation of nuclear extract was described previously (6).

Gel Retardation Assay—Analysis of *in vitro* synthesized or bacterially expressed receptor proteins or nuclear proteins by gel retardation was described previously (45). To analyze the effect of BAG-1 protein, *in vitro* synthesized BAG-1 protein was preincubated with receptor protein at room temperature for 10 min before the gel retardation assay. The oligonucleotides used for gel retardation assays were βRARE (TG-TAGGGTTCACCGAAAGTTCAGTC) (46); TREpal (TGAGGTCATGAC-CTGA) (45); DR-5-RARE(TGTAGGGTTCACACTGAGTTCACTCA); and DR-2-RARE(AGGTCAAAAGGTCAG).

GST Pull-down Assay—To analyze the interaction between BAG-1 and RAR, GST-BAG-1 fusion protein was immobilized on glutathione-Sepharose beads as described (52). As a control, GST prepared under the same conditions was also immobilized. The beads were preincubated with bovine serum albumin (1 mg/ml) at room temperature for 5 min. ^{35}S-Labeled *in vitro* synthesized receptor proteins (2 to 5 μl, depending on translation efficiency) Bcl-2 or Hsc70 were then added to the beads. The beads were then continuously rocked for 1 h at 4 °C in a final volume of 200 μl in EBC buffer (140 mM NaCl, 0.5% Nonidet P-40,

FIG. 3. **RAR and BAG-1 interact in yeast.** The RARα and BAG-1 cDNAs were cloned into the yeast expression vectors pGAD and pGBT, respectively. The resulting expression vectors were introduced into Y190 yeast cells. The yeast transformants were streaked on a filter and assayed for β-galactosidase activity. *11+424/Bag-1*, pGBT and pGAD/BAG-1; *11/Aγ+424*, pGBT/RARγ + pGAD; *11/Aγ+424/Bag-1*; pGBT RARγ + pGAD/BAG-1; *9/Xα+426*, pGBT/RXRα + pGAD; *9/Xα+426/Aγ*, pGBT/RXRα + pGAD/RARγ; *9/Xα+424/Bag-1*, pGBT/RXRα + pGAD/BAG-1; *9+426/Aγ*; pGBT + pGAD/RARγ; *9+424*, pGBT + pGAD.

100 mM NaF, 200 μM sodium orthovanadate, and 50 mM Tris, pH 8.0). After washing five times with NETN buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris, pH 8.0, 0.5% Nonidet P-40), the bound proteins were analyzed by SDS-polyacrylamide gel electrophoresis.

Two-hybrid Assay—For the yeast two-hybrid assay, the yeast two-hybrid system from CLONTECH Inc. (Palo Alto, CA) was used (52). BAG-1 cDNA was cloned into the yeast expression vector pGAD424 to generate an in-frame fusion with the Gal4 activation domain. RARγ or RXRα cDNAs were cloned into pGBT11 or pGBT9, respectively, to produce an in-frame fusion with Gal4 DNA binding domain. RARγ was also cloned into pGAD426 that contains Gal4 activation domain to study the interaction between RARγ and RXRα. The yeast reporter strain Y190 containing a LacZ reporter plasmid with Gal4 binding sites was used for transformation. β-Galactosidase activity was determined following the conditions provided by the manufacturer.

RESULTS

Inhibition of Retinoid Receptor DNA Binding by BAG-1—We investigated whether BAG-1 could interact with retinoid receptors by studying the effect of BAG-1 protein on binding of retinoid receptors to their target DNA sequences. *In vitro* synthesized RAR and RXR formed a strong RAR/RXR heterodimer complex with the TREpal as described previously (45). When increasing amounts of *in vitro* synthesized short BAG-1 isoform protein were incubated with RAR and RXR, the binding of RAR/RXR heterodimers was inhibited in a BAG-1 concentration-dependent manner (Fig. 1*a*). At a 5 M excess of BAG-1 protein relative to RAR/RXR, the binding was almost completely inhibited. The effect of BAG-1 on RAR/RXR binding was specific because similar amounts of estrogen receptor did not show any effect. BAG-1 also effectively inhibited the binding of TR/RXR to the TREpal probe (Fig. 1*b*), consistent with a prior report that BAG-1 can interact with TR (43). To study whether the inhibitory effect of BAG-1 on RAR/RXR heterodimer binding is specific to the TREpal, we used another RA responsive element (βRARE), which is derived from the RARβ promoter (46). As

FIG. 4. **Inhibition of transactivation activities of nuclear receptors by BAG-1.** *a*, inhibition of RARα activity on the TREpal by BAG-1. The TREpal-tk-CAT reporter plasmid was co-transfected into CV-1 cells with 100 ng of RARα expression vectors together with the indicated amounts of BAG-1 expression vector or the empty plasmid (pcDNA3) into CV-1 cells. Transfected cells were treated with ▨ or without ☐ 10^{-7} M *trans*-RA and assayed 24 h later for CAT activity. *b*, inhibition of RARα activity on the βRARE by BAG-1. The βRARE-tk-CAT was co-transfected with 100 ng of RARα expression vectors together with the indicated amounts of BAG-1 expression vector or the empty vector (pcDNA3) into CV-1 cells, Transfected cells were treated with ▨ or without ☐ 10^{-7} M *trans*-RA and assayed 24 h later for CAT activity. *c*, inhibition of RARβ activity on the TREpal by BAG-1. The TREpal-tk-CAT reporter (47) was co-transfected by either 100 ng of RARβ expression vector together with the indicated amounts of pcDNA3/BAG-1 or pcDNA3. Cells were treated with ▨ or without ☐ 10^{-7} M *trans*-RA. *d*, inhibition of TR/RXR activities by BAG-1 MHC-TRE-tk-CAT reporter plasmid was co-transfected with 100 ng of TRβ expression vectors together with the indicated amounts of BAG-1 expression vector or the empty vector (pcDNA3) into CV-1 cells. Transfected cells were treated with or without 10^{-7} M T$_3$ and assayed 24 h later for CAT activity. *e*, effect of BAG-1 on RXR homodimer activity on the TREpal. The TREpal-tk-CAT was cotransfected with 100 ng of RXRα expression vector together with the indicated amount of BAG-1 or empty vector. Cells were treated with ▨ or without ☐ 10^{-7} M 9-*cis*-RA.

shown in Fig. 1c, binding of RAR/RXR on the βRARE was also inhibited by the addition of BAG-1 protein. Similar results were obtained with other RAREs, including CRBPI-RARE and ApoAI-RARE (data not shown). Thus, inhibition of RAR/RXR binding to their target DNA sequences by BAG-1 is independent of RAREs.

We next determined whether inhibition of RAR/RXR heterodimer binding by BAG-1 is due to interaction of BAG-1 with RAR or RXR. Since *in vitro* synthesized RAR or RXR alone does not bind efficiently to RARE, we used bacterially expressed RAR or RXR protein. When a 5-fold molar excess of BAG-1 protein was added, the binding of RARγ was significantly inhibited, whereas binding of RXRα was not affected (Fig. 1d). These results suggest that inhibition of RAR/RXR or TR/RXR heterodimer DNA binding by BAG-1 is likely due to its interaction with RAR or TR but not with RXR.

Interaction of BAG-1 with Retinoid Receptors—To further study the interaction between BAG-1 and RAR, we used an *in vitro* GST pull-down assay. A GST-BAG-1 fusion protein was expressed in bacteria and immobilized on glutathione-Sepharose beads. The beads were then incubated with *in vitro* synthesized ^{35}S-labeled RAR or RXR protein. After extensive washing, the mixtures were analyzed on a SDS-polyacrylamide gel. In comparison to the input lane, significant amounts of labeled RAR but not RXR were retained by GST-BAG-1-Sepharose beads but not by GST control beads (Fig. 2). For control, Bcl-2, a known BAG-1 interacting protein (34), bound strongly to GST-BAG-1 beads. We also employed a BAG-1 mutant protein in which the last 47 amino acid residues are deleted from its C-terminal end (41). This mutant protein (BAG-1/Δc) can interact with Bcl-2 but not with Hsc70. Interestingly, labeled RAR but not RXR was also retained by the mutant BAG-1, thus implying that the interaction of BAG-1 with RAR is independent of its binding to Hsc70.

Interaction between RAR and BAG-1 was also evaluated by the two-hybrid assay in yeast. Fig. 3 shows that co-transformation of BAG-1 and RARγ significantly activated the reporter in β-gal filter assay, whereas co-transformation of BAG-1 and RXRα did not. Interaction between BAG-1 and RARγ was specific because co-transformation of either BAG-1 or RARγ with the corresponding empty vector did not activate the reporter gene. Thus, RAR and BAG-1 also interact in intact cells.

Inhibition of Transactivation Activity of Retinoid Receptors by BAG-1—To further examine the BAG-1-RAR interaction, we studied the effects of the short BAG-1 isoform on RAR transactivation activity on a number of RAREs by transient transfection assay. When CV-1 cells were transiently transfected with RARα expression vector together with either TREpal-tk-CAT (Fig. 4a) or βRARE-tk-CAT (Fig. 4b), *trans*-RA-induced reporter gene activity was markedly inhibited by co-transfection of BAG-1 expression plasmid in a concentration-dependent manner. The effect is specific to BAG-1 because co-transfection of similar amounts of empty expression vector (pcDNA3) did not inhibit *trans*-RA-induced gene expression. BAG-1 also showed inhibitory effect on *trans*-RA-induced RARβ activity on the TREpal. However, the *trans*-RA-independent RARβ activity was not affected. This suggests that ligand-dependent RAR activity is more sensitive to the inhibitory effect of BAG-1. A similar inhibitory effect of BAG-1 was also obtained when RARγ expression vector was used (data not shown). We also studied the effects of BAG-1 on thyroid hormone (T₃)-induced TRα activity, and we observed a significant inhibitory effect of BAG-1 on TRα (Fig. 4d), consistent with the ability of BAG-1 to bind the TR protein (Fig. 1b; Ref. 43). To determine the effect of BAG-1 on RXR homodimer activity, we co-transfected TREpal-tk-CAT reporter plasmid and RXRα expression vector. How-

FIG. 5. **Overexpression of BAG-1 reduces *trans*-RA-induced growth inhibition of breast cancer cells.** *a*, effect of constitutive BAG-1 expression on RA-induced growth inhibition in MCF-7 cells. The growth of BAG-1 stable transfectant, MCF-7/BAG-1(#3) (*shaded triangle*), parental MCF-7 cells (*black box*), and MCF-7 cells transfected with empty vector (MCF-7/neo, *shaded circle*) in the absence or presence of the indicated concentration of *trans*-RA was determined by the MTT assay. *b*, effect of constitutive BAG-1 expression on *trans*-RA-induced growth inhibition in ZR-75-1 cells. The growth of BAG-1 overexpressing transfectants 75-1/BAG-1(#5) (▲) and 75-1/BAG-1(#6) (♦), parental ZR75-1 cells (■), and ZR75-1 cells transfected with the empty vector (75-1/neo) (●) in the absence or presence of the indicated concentrations of *trans*-RA was determined by the MTT assay.

ever, the 9-*cis*-RA-induced RXRα homodimer activity was not affected by co-transfection of BAG-1 (Fig. 4e), consistent with our observation that BAG-1 does not interact with RXRα *in vitro* (Figs. 1d, 2, and 3).

Overexpression of BAG-1 Inhibits Trans-RA-induced Cancer Cell Apoptosis—The above data suggest that BAG-1 may function as a modulator of *trans*-RA-induced biological responses. We previously showed that *trans*-RA effectively inhibits the growth and induces apoptosis of some human breast cancer cell lines (5). We, therefore, stably expressed BAG-1 in human breast cancer cell lines MCF-7 and ZR-75-1. MCF-7/BAG-1(#3), 75-1/BAG-1(#5), and 75-1/BAG-1(#6) that stably expressed high levels of the transfected BAG-1 plasmid (data not shown) were chosen to examine the effect of BAG-1 overexpression on RA activities. As shown in Fig. 5a, *trans*-RA effectively inhibited the growth of parental MCF-7 and ZR-75-1 cells. However,

FIG. 6. **Overexpression of BAG-1 inhibits *trans*-RA-induced apoptosis of ZR-75-1 cells.** *a*, inhibition of *trans*-RA-induced apoptosis in ZR-75-1 cells. *b*, inhibition of *trans*-RA-induced apoptosis in MCF-7 cells. Cells were treated with 10^{-6} M *trans*-RA for 48 h, and DNA fragmentation was determined by the terminal deoxynucleotidyl transferase assay. Representative histograms show relative apoptotic cell numbers. *FL*, fluorescence.

the BAG-1-overexpressing clones displayed resistance to the growth inhibitory effects of *trans*-RA. The growth of the MCF-7/BAG-1(#3) was even stimulated by *trans*-RA (Fig. 5*a*). Although *trans*-RA did not stimulate the growth of 75-1/BAG-1(#5) and 75-1/BAG-1(#6) cells, its inhibitory effect on the growth of these cells was significantly reduced as compared with its effect on ZR-75-1 cells (Fig. 5*b*). The effect on *trans*-RA activity observed above was specific because clones stably transfected with the empty vector, MCF-7/neo and 75-1/neo, exhibited similar responses to *trans*-RA as that observed with the parental cell lines. Thus, BAG-1 partially abrogates the growth inhibitory effects of *trans*-RA on human breast cancer cells.

We next investigated the effects of BAG-1 on *trans*-RA-induced apoptosis of ZR-75-1 and MCF-7 cells using the terminal deoxynucleotidyl transferase assay. Extensive DNA fragmen-

tation was induced by *trans*-RA in ZR-75-1 and ZR-75-1/neo cells. In the typical experiment shown in Fig. 6*a*, about 39 and 33% of the ZR-75-1 and ZR-75-1/neo cells underwent apoptosis in response to *trans*-RA, respectively. However, ZR-75-1/BAG-1(#5) and ZR-75-1/BAG-1(#6) cells experienced much less DNA fragmentation under the same conditions, with only about 7 and 8% apoptotic cells, respectively. Similarly, the apoptogenic effect of *trans*-RA on MCF-7 cells was significantly reduced by BAG-1 overexpression (Fig. 6*b*). Thus, overexpression of BAG-1 inhibits *trans*-RA-induced apoptosis in breast cancer cells.

Overexpression of BAG-1 Abrogates Down-regulation of Bcl-2 by Trans-RA—Retinoids have been shown to down-regulate the expression of Bcl-2 in leukemia (11). We therefore studied whether BAG-1 affected RA-regulated expression of Bcl-2 in MCF-7 cells. Bcl-2 was highly expressed in MCF-7 cells, and its expression level was significantly reduced by *trans*-RA as de-

FIG. 7. **Overexpression of BAG-1 prevents inhibition of Bcl-2 expression by *trans*-RA in MCF-7 cells.** Cell lysates prepared from MCF-7/neo (*NEO*) and MCF-7/BAG-1(#3) (*BAG-1*) cells treated with 10^{-6} M *trans*-RA for the indicated time were electrophoresed in a SDS-polyacrylamide gel. After transfer to nitrocellulose membrane, Bcl-2 was detected with rabbit anti-Bcl-2 serum by Western blotting.

termined by immunoblotting. In MCF-7/BAG-1(#3)-stable transfectant, however, treatment of *trans*-RA had little or no effect on Bcl-2 expression (Fig. 7). These data suggest that BAG-1 may inhibit *trans*-RA-induced apoptosis at least in part through its effects on *trans*-RA-regulated genes, such as *Bcl-2*.

To further study the effect of BAG-1 on RAR-mediated gene regulation, we prepared nuclear extract from MCF-7, MCF-7/neo, and MCF-7/BAG-1(#3) cells and analyzed their binding to various RAREs, including βRARE, DR-5-type RARE, and DR-2-type RARE. As shown in Fig. 8*a*, extracts from MCF-7 and MCF-7/neo showed strong binding complex to these RAREs, whereas binding of the slow-migrating complex observed in MCF-7 and MCF-7/neo cells was strongly inhibited in MCF-7/BAG-1(#3) cells. To determine the nature of the slow-migrating complex, extract from MCF-7 cells was incubated with either anti-RAR (α-RAR) or anti-RXR (α-RXR) antibody or nonspecific preimmune serum prior to DNA binding reaction. Fig. 8*b* shows that either anti-RAR or anti-RXR antibody, but not nonspecific serum, completely inhibited the formation of the complex, suggesting that the complex contains RAR and RXR. These data further demonstrate that overexpression of BAG-1 inhibits RAR/RXR binding and suggest that the alteration of RAR transcriptional activity may contribute to the effect of BAG-1 on RA responses.

DISCUSSION

Previously, it was reported that BAG-1 (RAP46) can interact with several steroid hormone receptors (43). However, the biological effects of the interaction are unknown. In this report, we show that the short BAG-1 isoform that is known to be predominantly expressed in cytoplasm (35) can antagonize RAR activity through its direct interaction with RAR. Using gel retardation assays, we observed that BAG-1 inhibits binding of RAR/RXR heterodimers to several RAREs (Fig. 1). In GST-pull down assay, we found that BAG-1 directly interacts with RAR in solution (Fig. 2). By using yeast two-hybrid assays (Fig. 3), we showed that the BAG-1-RAR interaction could occur *in vivo*. Moreover, a functional interaction was demonstrated by our observation that co-transfection of BAG-1 inhibits *trans*-RA-induced RAR transactivation activities on several RAREs (Fig. 4). Furthermore, RAR/RXR RARE binding was abrogated in MCF-7 cells that express transfected BAG-1 (Fig. 8). Thus, the interaction of BAG-1 with steroid hormone receptors can be extended to RAR. We also present evidence here that BAG-1 can similarly prevent TR DNA binding and transactivation activity. However, BAG-1 does not interact with all nuclear hormone receptors, as shown here by the failure of BAG-1 to bind to and modulate the activity of RXR (Figs. 1*d*, 2, 3, and 4*e*).

Activation or repression of gene transcription by nuclear hormone receptors requires their interaction with multiple cellular co-regulatory factors. These include receptor co-activators, which exert their effect on receptor transactivation activ-


FIG. 8. **Overexpression of BAG-1 inhibits DNA binding of RAR/RXR heterodimer in MCF-7 cells.** *a*, an equal amount (3 μg) of nuclear extracts prepared from MCF-7, MCF-7/neo, and MCF-7/BAG-1(#3) was analyzed by gel retardation assay using βRARE, DR-5-type RARE (*DR-5*) or DR-2-type RARE (*DR-2*) as a probe. *b*, effects of anti-RXR (α*RXR*) and anti-RAR (α*RAR*) antibodies on the binding of the slow-migrating binding complex. Nuclear extract (3 μg) from MCF-7 cells was incubated with antibody (*Ab*) for 30 min at room temperature before performance of the gel retardation assay using the βRARE as a probe. The *arrow* indicates the slow-migrating complex, which had a binding that was inhibited by either α*RXR* or α*RAR* but not by nonspecific preimmune serum (*NI*).

ity by mediating transcription-initiation complex formation and affecting chromatin structure (15), and receptor co-repressors, which bind to receptors in the absence of ligand and actively repress target gene transcription by impairing the activity of the basal transcription machinery (25). BAG-1 appears to function differently from receptor co-activators or co-repressors. It does not induce ligand-dependent gene activation nor does it cause repression of target gene transcription in the absence of ligand (Fig. 4*a*). Instead, interaction of RAR and BAG-1 resulted in inhibition of RAR DNA binding (Fig. 1) and *trans*-RA-induced RAR transactivation activities (Fig. 4). Thus, it may function as a modulator of RAR activities through the mechanisms that resemble the effect of AP-1, which was previously shown to inhibit *trans*-RA-induced RAR activity by preventing RAR binding to target DNA sequences in promoters (27). However, whether BAG-1 affects recruitment of co-activator or co-repressor by RAR remains to be determined.

The mechanism by which BAG-1 inhibits RAR binding to DNA and transactivation activity remains to be elucidated. Recently, BAG-1 was reported to bind tightly with Hsp70/Hsc70-family proteins and modulate their activity (40–42). Although the role of molecular chaperones in transcriptional activation by retinoid receptors remains controversial (49, 50), Hsp70/Hsc70 and other heat shock proteins are known to participate in the regulation of several other steroid hormone receptors (44). It is therefore tempting to speculate that BAG-1 may also influence RAR activity through Hsp70/Hsc70-mediated conformational changes that prevent it from binding DNA and transactivating retinoid-responsive target genes. Interestingly, a deletion mutant of BAG-1 lacking its C-terminal 47 amino acids, which does not bind to Hsc70, was capable of

binding to RAR *in vitro* (Fig. 2). Thus, the domains in BAG-1 required for interactions with RAR and Hsp70 appear to be separable. Unfortunately, when expressed in mammalian cells, the BAG-1 mutant protein was unstable, precluding functional evaluation of its effects on RAR-mediated gene expression. Thus, the relevance of BAG-1 interactions with Hsp70-family proteins to its function as inhibitor of RAR remains to be determined.

One of the interesting features of BAG-1 is its ability to promote cell survival (34, 36, 37). The effect was previously attributed to its interaction with Bcl-2 (34). In addition, BAG-1 interacts with platelet-derived growth factor and hepatocyte growth factor receptors, enhancing their ability to transduce signals that promote cell survival (39). BAG-1 can also bind to Raf-1 and activate its kinase activity (38). Our observations that overexpression of BAG-1 inhibits *trans*-RA-induced apoptosis (Fig. 6) and prevents *trans*-RA-induced down-regulation of Bcl-2 expression (Fig. 7) suggest that interaction with RAR may represent another mechanism by which BAG-1 promotes cell survival. These observations also suggest that overexpression of BAG-1 may contribute to retinoid resistance in certain malignancies. Taken together with recent observations that BAG-1 protein levels are elevated in breast and prostate cancers (51), BAG-1 may represent an important regulator of cell survival and growth, which may contribute in multiple ways to tumorigenesis and resistance to therapy.

Note Added in Proof—The longer isoform of BAG-1, BAG-1L, has been reported recently to enhance androgen receptor transactivation, implying that BAG-1 family proteins may either potentiate or suppress the actions of specific nuclear receptors (Froesch, B. A., Takayama, S., and Reed, J. C. (1998) *J. Biol. Chem.* **273**, 11660–11666).

REFERENCES

1. White, E. (1996) *Genes Dev.* **10**, 1–15
2. Reed, J. C. (1994) *J. Cell. Biol.* **124**, 1–6
3. Gudas, L. J., Sporn, M. B., and Roberts, A. B. (1994) in *The Retinoids* (Sporn, M. B., Roberts, A. B., and Goodman, D. S., eds) pp. 443–520, Raven Press, New York
4. Hong, W. K., and Itri, L. M. (1994) in *The Retinoids* (Sporn, M. B., Roberts, A. B., and Goodman, D. S., eds) pp. 597–630, Raven Press, Ltd., New York
5. Liu, Y., Lee, M.-O., Wang, H.-G., Li, Y., Hashimoto, Y., Klaus, M., Reed, J. C., and Zhang, X.-k. (1996) *Mol. Cell. Biol.* **16**, 1138–1149
6. Wu, Q., Dawson, M. I., Zheng, Y., Hobbs, P. D., Agadir, A., Jong, L., Li, Y., Liu, R., Lin, B., and Zhang, X.-k. (1997) *Mol. Cell. Biol.* **17**, 6598–6608
7. Li, Y., Dawson, M. I., Agadir, A., Lee, M.-O., Jong, L., Hobbs, P. D., and Zhang, X.-k. (1998) *Int. J. Cancer* **75**, 88–95
8. Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M, Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., and Meltzer, P. S. (1997) *Science* **277**, 965–968
9. Chao, W. R., Hobbs, P. D., Jong, L., Zhang, X.-k., Zheng, Y., Wu, Q., Shroot, B., and Dawson, M. I. (1997) *Cancer Lett.* **115**, 1–7
10. Ponzoni, M., Bocca, P., Chiesa, V., Decensi, A., Pistoia, V., Raffaghello, L., Rozzo, C., and Montaldo, P. G. (1995) *Cancer Res.* **55**, 853–861
11. Elstner, E., Linker-Israeli, M., Umiel, T., Le, J., Grillier, I., Said, J., Shintaku, I. P., Krajewski, S., Reed, J. C., Binderup, L., and Koeffler, H. P. (1996) *Cancer Res.* **56**, 3570–3576
12. Zhang, X.-k., and Pfahl, M. (1993) *TEM* **4**, 156–162
13. Kastner, P., Mark, M., and Chambon, P. (1995) *Cell* **83**, 859–869
14. Mangelsdorf, D. J., and Evans, R. M. (1995) *Cell* **83**, 841–850
15. Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., and Tung, L. (1996) *Mol. Endocrinol.* **10**, 1167–1177
16. Onate, S. A., Tsai, S. Y., Tsai, M.-J., and O'Malley, B. W. (1995) *Science* **270**, 1354–1357
17. Lee, J. W., Ryan, F., Swaffield, J. C., Johnston, S. A., and Moore, D. D. (1995) *Nature* **374**, 91–94
18. Ledouarin, B., Zechel, C., Garnier, J. M., Lutz, Y., Tora, L., Pierrat, B., Heery, D., Gronemeyer, H., Chambon, P., and Losson, R. (1995) *EMBO J.* **14**, 2020–2033
19. Cavailles, V., Dauvois, S., Horset, F. L., Lopez, G., Hoare, S., Kushner, P. J., and Parker, M. G. (1995) *EMBO J.* **14**, 3741–3751
20. Voegel, J. J., Heine, M. J. S., Zechel, C., Chambon, P., and Gronemeyer, H. (1996) *EMBO J.* **15**, 3667–3675
21. Hong, H., Kohli, K., Trivedi, A., Johnson, D. L., and Stallcup, M. R. G. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 4948–4952
22. Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C., and Brown, M. (1994) *Science* **264**, 1455–1458
23. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) *Cell* **85**, 403–414
24. Chen, H., Lin, R. J., Schlitz, R. L., Chakravarti, D., Nash, A., Nagy, Y., Privalsky, M. L., Nakatani, Y., and Evans, R. M. (1997) *Cell* **90**, 569–580
25. Horlein, A. J., Naar, A. M., Heinzel, T., Torchia, J., Gloss, B., Kurokawa, R., Ryan, A., Kamei, Y., Soderstrom, M., Glass, C. K., and Rosenfeld, M. G. (1995) *Nature* **377**, 397–404
26. Chen, J. D., and Evans, R. M. (1995) *Nature* **377**, 454–457
27. Pfahl, M. (1993) *Endocr. Rev.* **14**, 651–658
28. Kochhar, D. M., Jiang, H., Harnish, D. C., and Soprano, D. R. (1993) *Prog. Clin. Biol. Res.* **383**, 815–825
29. Nagy, L., Thomazy, V. A., Shipley, G. L., Fesus, L., Lamph, W., Heyman, R. A., Chandraratna, R. A., and Davies, P. J. (1995) *Mol. Cell Biol.* **15**, 3540–3551
30. Fanjul, A. N., Delia, D., Pierotti, M. A., Rideout, D., Qiu, J., and Pfahl, M. (1996) *J. Biol. Chem.* **271**, 22441–22446
31. Fanjul, A. N., Bouterfa, H., Dawson, M., and Pfahl, M. (1996) *Cancer Res.* **56**, 1571–1577
32. Yang, Y., Minucci, S., Ozato, K., Heyman, R. A., and Ashwell, J. D. (1995) *J. Biol. Chem.* **270**, 18672–18677
33. Steller, H. (1995) *Science* **267**, 1445–1449
34. Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J. A., and Reed, J. C. (1995) *Cell* **80**, 279–284
35. Packham, G., Brimmell, M., and Cleveland, J. L. (1997) *Biochem J.* **328**, 807–813
36. Clevenger, C. V., Thickman, K., Ngo, W., Chang, W.-P., Takayama, S., and Reed, J. C. (1997) *Mol. Endocrinol.* **11**, 608–618
37. Takaoka, A., Adachi, M., Okuda, H., Sato, S., Yawata, A., Hinoda, Y., Takayama, S., Reed, J. C., and Imai, K. (1997) *Oncogene* **14**, 2971–2977
38. Wang, H.-G., Takayama, S., Rapp, U. R., and Reed, J. C. (1996) *Proc. Natl. Acad. Sci. U. S. A.* **93**, 7063–7068
39. Bardelli, A., Longati, P., Albero, D., Goruppi, S., Schneider, C., Ponzetto, C., and Comoglio, P. M. (1996) *EMBO J.* **15**, 6205–6212
40. Hohfeld, J., and Jentsch, S. (1997) *EMBO J.* **16**, 6209–6216
41. Takayama, S., Bimston, D. N., Matsuzawa, S., Freeman, B. C., Aime-Sempe, C., Xie, Z., Morimoto, R. I., and Reed, J. C. (1997) *EMBO J.* **16**, 4887–4896
42. Zeiner, M., Gebauer, M., and Gehring, U. (1997) *EMBO J.* **16**, 5483–5490
43. Zeiner, M., and Gehring, U. (1995) *Proc. Natl. Acad. Sci. U. S. A.* **92**, 11456–11469
44. Pratt, W. B., and Toft, D. O. (1997) *Endocr. Rev.* **18**, 306–360
45. Zhang, X.-k., Hoffmann, B., Tran, P. B., Graupner, G., and Pfahl, M. (1992) *Nature* **355**, 441–446
46. Hoffmann, B., Lehmann, J. M., Zhang, X.-k., Hermann, T., Graupner, G., and Pfahl, M. (1990) *Mol. Endocrinol.* **4**, 1734–1743
47. Hermann, T., Hoffmann, B., Zhang, X.-k., Tran, P., and Pfahl, M. (1992) *Mol. Endocrinol.* **6**, 1153–1162
48. Zhang, X.-k., Lehmann, J., Hoffmann, B., Dawson, M. I., Cameron, J., Graupner, G., Hermann, T., Tran, P., and Pfahl, M. (1992) *Nature* **358**, 587–591
49. Dalman, F. C., Sturzenbecker, L. J., Levin, A. A., Luca, D. A., Perdew, G. H., Petkovitch, M., Chambon, P., Grippo, J. F., and Pratt, W. B. (1991) *Biochemistry* **30**, 5605–5608
50. Holley, S. J., and Yamamoto, K. R. (1995) *Mol. Cell. Biol.* **6**, 1833–1842
51. Takayama, S., Krajewski, S., Krajewska, M., Kitada, S., Zapata, J., Kochel, K., Knee, D., Miller, G., Scudiero, D., Tudor, G., Sausville, E., and Reed, J. C. (1998) *Cancer Res.*, in press
52. Wu, Q., Li, Y., Liu, R., Agadir, A., Lee, M.-O., Liu, Y., and Zhang, X.-k. (1997) *EMBO J.* **16**, 1656–1669